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ABSTRACT		Amyotrophic	 Lateral	 Sclerosis	 (ALS)	 and	 Frontotemporal	 Dementia	 (FTD)	 are	neurodegenerative	 diseases	 affecting	 motor	 neurons	 and	 neurons	 in	 the	frontal/temporal	 lobes	 of	 the	 cortex,	 respectively.	 A	 pathological	 hallmark	 of	both	ALS	and	FTD	patients	are	neuronal	and	glial	proteinaceous	inclusions	in	the	affected	brain	regions.	In	a	subset	of	patients,	these	inclusions	contain	the	RNA-binding	 protein	 (RBP)	 Fused	 in	 Sarcoma	 (FUS).	 Although	 most	 cases	 are	sporadic,	 there	 are	 familial	 cases	 in	 which	 several	 causal	 genes	 have	 been	identified	 for	 both	 diseases.	 In	 a	 subset	 of	 ALS	 patients,	 several	 ALS-causing	mutations	 in	 the	 FUS	 gene	 have	 been	 identified.	 Disease-associated	 FUS	mutations	 are	 found	 primarily	 in	 the	 nuclear	 localization	 signal	 (NLS)	 of	 FUS.	NLS	 mutations	 impair	 nuclear	 import	 of	 FUS	 and	 hence	 result	 in	 increased	cytosolic	accumulation	of	FUS.		As	 FUS	 is	 primarily	 localized	 in	 the	 nucleus	 and	 plays	 important	 roles	 in	transcription,	 alternative	 splicing,	 DNA	 damage	 repair	 and	 miRNA	 biogenesis,	most	 studies	 have	 focused	 on	 the	 nuclear	 role	 of	 FUS.	 In	 recent	 years,	 a	cytoplasmic	 role	 for	 FUS	 has	 become	 more	 evident,	 e.g.	 in	 the	 regulation	 of	mRNA	stability	or	mRNA	transport.	In	ALS	and	FTD	patients,	FUS	is	partially	lost	from	 the	 nucleus	 and	 found	 in	 cytoplasmic	 aggregates,	 resulting	 in	 loss	 of	 the	nuclear	 function	 of	 FUS	 as	 well	 as	 toxic	 gain-of-function	 by	 cytosolic	 FUS	aggregates.			This	leads	to	the	question	as	to	the	effect	of	the	cytosolic	mislocalization	of	FUS.	In	 order	 to	 determine	 if	 this	 mislocalization	 results	 in	 an	 altered	 FUS	interactome,	I	aimed	to	isolate	FUS	mRNP	complexes	from	a	FUS	mutant	mouse	model	and	identify	both	RNA	and	protein	interactors.	The	Fus	ΔNLS/+mouse	model	was	created	by	removing	the	FUS	NLS,	causing	FUS	cytoplasmic	mislocalization	and	resulting	in	an	early	cortical	and	a	late	motor	phenotype.	Using	the	cytosolic	fraction	 from	 the	 cortices	 of	 50	 day	 old	 Fus	 ΔNLS/+	 mice,	 I	 performed	immunoprecipitation	(IP)	of	FUS	followed	by	mass	spectrometry	(MS)	and	RNA	sequencing	 (RNASeq).	 I	 identified	an	altered	FUS	 interactome,	both	on	an	RNA	
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and	protein	level.	Differentially	bound	RNAs	included	those	whose	proteins	are	involved	 in	 transcription,	 proteasomal	 activity,	 nicotinic	 signaling	 and	 RNA	binding.	I	found	changes	in	alternatively	spliced	mRNAs	present	in	the	cytoplasm	of	these	mice,	including	Ddhd1	and	Ptprf1.	This	could	indicate	a	nuclear	loss-of-function	of	FUS	and	hence	missplicing	of	FUS	 target	 genes.	Differential	protein	interactors	 included	 those	 important	 to	 synapse	 function	 and	 RNA	 regulation.	The	 altered	 FUS	 interactome	 caused	 by	 FUS	 cytosolic	mislocalization	may	 not	only	 result	 in	 expression	 of	 alternative	 isoforms,	 but	 also	 perhaps	 affect	 RNA	stability	 and	 localization	 resulting	 in	 impaired	 neuronal	 function.	 This	 study	provides	 new	 insights	 into	 the	 pathomechanisms	 of	 FUS-associated	neurodegeneration.				
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I.	INTRODUCTION			
1.	Amyotrophic	Lateral	Sclerosis	and	Frontotemporal	Dementia		Amyotrophic	 Lateral	 Sclerosis	 (ALS)	 and	 Frontotemporal	 Dementia	 (FTD)	 are	devastating	 neurodegenerative	 diseases.	 Although	 they	 affect	 different	 brain	regions	 and	 therefore	 present	 with	 different	 phenotypes,	 they	 overlap	 both	genetically	and	neuropathologically.		
1.1	Clinical	Presentation	and	Causes	of	Amyotrophic	Lateral	Sclerosis			ALS	 involves	 the	 degeneration	 of	 upper	 and	 lower	motor	 neurons	 responsible	for	 voluntary	 muscle	 movements,	 such	 as	 walking,	 talking	 and	 chewing.	 	 The	upper	motor	neurons	send	signals	to	the	lower	motor	neurons	in	the	spinal	cord.		These	neurons	 in	 turn	 send	 signals	 to	 the	 appropriate	muscle.	 	Without	 signal	from	 the	 neurons,	 the	 muscle	 becomes	 denervated	 and	 eventually	 atrophies.	Typical	 onset	 occurs	between	55-75	years	of	 age,	 and	occurs	 initially	 either	 in	the	arms	or	legs	(limb	onset)	or	in	the	mouth	(bulbar	onset).	Symptoms	include	muscle	spasms,	weakness,	tightness,	and	spasticity.	Muscle	atrophy	then	spreads	to	the	rest	of	the	body.	Most	people	die	of	respiratory	failure	within	3-5	years	of	symptom	onset	 (van	Es	MD	et	al.	2017;	van	Langenhove,	van	der	Zee,	 and	van	Broeckhoven	 2011;	 Taylor,	 Brown,	 and	 Cleveland	 2016).	 ALS	 is	 typically	diagnosed	 based	 on	 a	 patient’s	 symptoms,	 medical	 history	 and	electromyography	(EMG).		Approximately	90%	of	ALS	cases	are	sporadic,	 the	remaining	cases	are	genetic,	more	 than	 a	 dozen	 genes	 have	 been	 identified	 (Taylor,	 Brown,	 and	 Cleveland	2016).	 Although	 some	 speculation	 has	 been	 made	 regarding	 the	 possible	environmental	 influences,	 nothing	 definitive	 has	 been	 found.	 Mutations	 in	several	 key	 genes	 have	 been	 identified.	 	 The	 first	 gene	 to	 be	 discovered	 to	 be	associated	with	ALS	was	SOD1	(Rosen	et	al.	1993).	Since	then,	ANG,	VCP,	TARDBP,	
FUS,	hnRNPA1,	and	C9orf72	are	some	among	several	that	have	been	added	to	the	
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growing	list	(Ghasemi	and	Brown	2018).	The	cause	of	sporadic	ALS	is	unknown,	while	 several	 genome-wide	 association	 studies	 have	 identified	 various	associated	loci,	many	were	not	reproducible	(Ajroud-Driss	and	Siddique	2014).	A	few	 genes	 have	 been	 confirmed	 in	 a	 larger	 cohort	 to	 mediate	 susceptibility	and/or	modulate	survival,	such	as	UNC13A,	ELP3	and	ATXN2	(van	Blitterswijk	et	al.	2014;	M.-D.	Wang	et	al.	2017).		Several	studies	have	identified	problems	in	RNA	processing	in	ALS,	which	should	not	 be	 surprising	 as	 a	 large	 number	 of	 the	 implicated	 genes	 encode	 for	 RNA	binding	 proteins,	 e.g.	 TDP-43,	 FUS,	 hnRNPA1.	 Additionally	 post-mortem	pathology	shows	accumulation	of	TDP-43	and	FUS	in	aggregates	(Neumann	et	al.	2006;	 Vance	 et	 al.	 2009;	 Kwiatkowski	 et	 al.	 2009).	 This	 pathology	 will	 be	described	further	in	the	overlap	of	FTD	and	ALS	section.		
1.2	Clinical	Presentation	and	Causes	of	Frontotemporal	Dementia		Frontotemporal	 Dementia	 is	 the	 second	 most	 common	 presenile	 dementia,	 it	occurs	10-15	per	100,000	 individuals	aged	45-65	 (Rademakers,	Neumann,	 and	Mackenzie	2012).	Mutations	are	found	in	approximately	50%	of	patients	with	a	family	 history	 (Ling,	 Polymenidou,	 and	 Cleveland	 2013),	 resulting	 in	degeneration	of	the	frontal,	temporal	and	insular	lobes	of	the	cortex.	Rather	than	just	one	disease,	FTD	is	actually	a	group	of	conditions	divided	into	the	following	categories:	 Behavioral	 variant	 frontotemporal	 dementia	 (bvFTD),	 semantic	variant	 primary	 progressive	 aphasia	 (svPPA),	 and	 non-fluent/agrammatic	variant	 primary	 progressive	 aphasia	 (nfvPPA)	 (Bang,	 Spina,	 and	 Miller	 2015).	These	 different	 forms	 lead	 to	 slightly	 different	 behaviors	 and	 language	symptoms	depending	on	the	region	of	the	brain	that	degenerates.		Initial	 symptoms	 generally	 include	 a	 gradual	 change	 in	 behavior,	 language	dysfunction	 and	 possibly	 physical	 weakness.	 	 For	 example,	 patients	may	 have	increased	impulsivity	and	apathy,	as	well	as	 loss	of	sympathy	and	poor	 insight.	The	language	dysfunction	involved	in	one	of	the	language	variants	of	FTD	results	
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in	difficulty	expressing	oneself,	although	the	memory	is	intact	(Bang,	Spina,	and	Miller	2015).		Thus	 far,	 a	 handful	 of	 genes	 have	 been	 identified	 to	 cause	 FTD:	 microtubule-associated	 protein	 Tau	 (MAPT)	 (Hutton	 et	 al.	 1998)	 and	 progranulin	 (PRGN)	(Baker	et	al.	2006;	Cruts	et	al.	2006)	and	C9ORF72	(Renton	et	al.	2011;	DeJesus-Hernandez	et	al.	2011).	In	very	rare	cases,	mutations	in	TARDBP	and	FUS	cause	FTD	(Borroni	et	al.	2009;	Benajiba	et	al.	2009).		
1.3.	Overlap	between	ALS	and	FTD		Approximately	 15%	 of	 FTD	 or	 ALS	 patients	 reach	 the	 criteria	 for	 the	 other	disease	 (Ringholz	 et	 al.	 2005;	 Wheaton	 et	 al.	 2007).	 FTD	 and	 ALS	 overlap	genetically,	 pathologically	 and	 clinically.	 The	 hexanucleotide	 expansion	 in	
C9ORF72	 has	been	 found	 to	be	a	 common	genetic	 cause	 for	both	ALS	and	FTD	(Renton	et	al.	2011;	DeJesus-Hernandez	et	 al.	2011).	Mutations	 in	other	genes,	such	as	UBQLN2	can	cause	either	ALS	or	FTD	(Figure	1).				
		
	The	 neuropathological	 presentation	 of	 the	 diseases	 is	 also	 very	 similar.	While	usually	 affecting	 different	 parts	 of	 the	 nervous	 system,	 both	 ALS	 and	 FTD	 can	contain	 either	 TDP-43	 or	 FUS	 inclusions.	 	 These	 inclusions	 not	 only	 occur	 in	familial	 cases	 of	 ALS	 and	 FTD,	 but	 also	 in	 sporadic	 (Neumann	 et	 al.	 2006).	 In	most	 ALS	 cases	 and	 approximately	 50%	 of	 FTD	 cases,	 TDP-43	 loss	 from	 the	
Figure	1.	Genetic	overlap	between	ALS	and	FTD.	Mutations	in	genes	such	as	
SOD1	or	PGRN	only	cause	ALS	or	FTD,	respectively,	while	the	hexanucleotide	repeat	expansion	in	C9ORF72	can	cause	either	or	both	ALS	and	FTD.	
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nucleus	 occurs	 and	 cytosolic	 aggregates	 are	 present,	 and	 in	 rare	 cases	intranuclear	aggregates	are	found	(Ling,	Polymenidou,	and	Cleveland	2013).	 	In	even	rarer	cases	of	ALS,	but	slightly	more	often	in	FTD,	FUS	is	mislocalized	and	aggregated	 (Neumann	et	al.	2009;	Kwiatkowski	et	al.	2009;	Vance	et	al.	2009).	Since	 these	 RNA-binding	 proteins	 are	 important	 in	 multiple	 steps	 in	 RNA	metabolism,	 it	 is	 believed	 that	RNA	processing	 errors	may	play	 a	 large	 role	 in	ALS	and	FTD	pathogenesis.		Several	groups	have	shown	that	mutations	in	either	TDP-43	or	FUS	result	 in	differential	RNA	expression.	Not	only	are	mRNA	levels	altered,	but	alternate	splice	variants	are	also	produced.	Further,	complete	loss	of	either	 TDP-43	 or	 FUS	 results	 in	 dramatic	 changes	 to	 the	 transcriptome.	Additionally,	 there	 is	 some	overlap	of	 the	affected	 transcripts	between	TDP-43	and	FUS	(Lagier-Tourenne	et	al.	2012;	Polymenidou	et	al.	2011).			Aside	from	RNA	binding	proteins,	other	classes	of	genes	that	have	been	found	to	be	mutated	 are	 those	 of	 autophagy	 and	 cytoskeleton/transport.	 Autophagy	 or	proteasome-related	 genes	 such	 as	 UBQLN2,	 p62/SQSTM1,	 TBK1,	 VCP	 and	cytoskeletal	genes	such	as	MAPT	and	TUBA4A	are	among	the	growing	list	of	the	genes	associated	with	ALS	and/or	FTD	(reviewed	in	(Nguyen,	van	Broeckhoven,	and	van	der	Zee	2018)).		
1.4	Current	Treatments		Currently	there	is	no	cure	for	either	ALS	or	FTD.	There	are	a	few	drugs	for	both	diseases	 that	 slightly	 slow	 the	 progression	 and	 alleviate	 symptoms.	 Riluzole,	 a	compound	 that	 blocks	 tetrodotoxin-sensitive	 sodium	 channels,	 kainate	 and	NMDA	 receptors,	 may	 increase	 survival	 of	 ALS	 patients	 by	 a	 few	 months	(Bensimon,	 Lacomblez,	 and	 Meininger	 1994).	 Edaravone,	 an	 anti-oxidant,	 has	been	 shown	 to	 improve	 daily	 function	 for	 individuals	 with	 ALS	 (Takei	 et	 al.	2017).	 At	 this	moment,	 there	 is	 no	way	 to	 slow	 the	 progression	 of	 FTD.	Most	commonly,	 patients	 are	 given	 antidepressants	 and	 antipsychotics.	 Both	treatment	approaches	may	reduce	behavioral	problems	in	some	patients.			
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2.	RNA	Binding	Proteins	in	ALS	and	FTD			As	 previously	 mentioned,	 several	 RNA	 binding	 proteins	 (RBPs)	 have	 been	implicated	 in	 the	 disease	 pathogenesis	 of	 ALS	 and	 FTD.	 Mutations	 in	 genes	encoding	 for	TDP-43,	FUS,	TAF15,	EWSR1,	hnRNPA1,	hnRNPA2B1	and	TIA1	have	all	 been	 reported	 to	 cause	 ALS	 or	 FTD,	 while	 an	 intermediate	 expansion	 in	
ATXN2	is	associated	with	an	increased	risk	for	ALS.	TDP-43	was	initially	isolated	from	the	 inclusions	 found	 in	 the	CNS	of	ALS	and	FTD	patients.	ALS-	associated	mutations	in	TDP-43	alter	axonal	morphology	and	mRNA	transport.	Expression	of	 mutant	 TDP-43	 in	 both	 zebrafish	 larvae	 and	 mice	 in	 the	 CNS	 results	 in	neuromuscular	junction	(NMJ)	defects	and	impaired	transmission	(Arnold	et	al.	2013;	 Armstrong	 and	 Drapeau	 2013).	 Not	 only	 do	 TDP-43	 mutations	 affect	axons,	but	also	dendritic	morphology	and	RNA	transport.	Expression	of	mutant	TDP-43	 in	 either	mouse	or	 rat	 neurons	 results	 in	mislocalization	of	TDP-43	 to	the	cytosol,	abnormally	small	neuritic	processes	and	larger,	less	mobile,	TDP-43	containing	granules	(Han	et	al.	2013;	Liu-Yesucevitz	et	al.	2014).		
2.1	FUS	(Fused	in	Sarcoma)	protein		FUS	(also	called	TLS),	a	FET	protein	family	member,	is	a	526	amino	acid	protein	that	was	 originally	 identified	 as	 a	 proto-oncogene	 in	 liposarcomas,	 as	 a	 fusion	protein	 caused	 by	 translocation	 of	 the	 prion-like	 domain	 of	 FUS	 with	 CHOP	(Crozat	et	al.	1993).	FUS	is	comprised	of	an	N-terminal	prion-like	low	complexity	(LC)	domain,	 three	RGG	domains,	an	RNA	binding	 (RRM)	domain,	a	 zinc	 finger	domain	(ZnF)	and	finally	a	nuclear	localization	signal	(NLS)	(Figure	2).							
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		The	 low	 complexity	 N-terminal	 domain,	 comprised	 primarily	 of	 serines,	tyrosines,	glycines	and	glutamines,	 is	 thought	to	mediate	aggregation	(Burke	et	al.	2015;	Murakami	et	al.	2015;	Patel	et	al.	2015;	S.	Sun	et	al.	2015)	and	acts	as	a	transcriptional	 activation	 domain	 (Rabbitts	 et	 al.	 1993;	 Crozat	 et	 al.	 1993).	Mutations	 in	 this	 domain	 promote	 liquid-to-solid	 phase	 transition	 and	aggregation	 (Patel	et	al.	2015).	The	nucleic	acid	binding	domains,	 consisting	of	an	RRM,	three	RGG	and	a	ZnF	domain,	mediate	protein-RNA	interactions,	as	well	as	protein-protein	 interactions.	 Finally,	 the	non-classical	 proline-tyrosine	 (PY)-NLS	(Lee	et	al.	2006)	plus	the	RGG3	domain	make	up	the	NLS	for	FUS	(Dormann	et	al.	2012).	TNPO1	binds	the	FUS	NLS,	mediating	 import	 from	the	cytosol	 into	the	 nucleus	 (Lee	 et	 al.	 2006).	 Mutations	 in	 the	 NLS	 decrease	 TNPO1	 binding	therefore	disrupting	nuclear	import.		Most	 of	 the	 ALS-associated	 FUS	mutations,	 such	 as	 R521G,	 R522G,	 R524S	 and	P525L,	occur	in	the	RGG3-PY	domain	of	FUS	(Kwiatkowski	et	al.	2009;	Dormann	and	 Haass	 2013;	 Vance	 et	 al.	 2009),	 resulting	 in	 various	 degrees	 of	 cytosolic	mislocalization;	 the	 higher	 degree	 of	 cytosolic	mislocalization,	 the	 quicker	 the	disease	progression	(Dormann	et	al.	2010).				
Figure	2.	The	domain	structure	and	disease-associated	mutations	of	FUS.	FUS	is	made	up	of	an	N-terminal	LC	domain	(grey),	3	RGG	domains	(blue),	an	RRM	domain	(red),	a	ZnF	(purple)	and	a	C-terminal	PY-NLS	(orange).	Black	lines	indicate	identified	disease-associated	mutations.	
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3.	The	Life	of	an	RNA	in	Neurons		
3.1.	Transcription,	Capping	and	Splicing		The	life	of	any	eukaryotic	RNA	begins	with	transcription	in	the	nucleus.	As	soon	as	 the	pre-mRNA	emerges	 from	 the	RNA	polymerase,	 it	 is	modified	by	 several	RNA	 binding	 proteins.	 The	 following	 modifications	 occur:	 capping,	 splicing,	addition	 of	 a	 poly(A)	 tail	 and	RNA	 editing.	 Capping	 occurs	 co-transcriptionally	and	 consists	 of	 a	 terminal	7-methylguanosine	 group;	 the	5’	 cap	 is	 required	 for	ribosomal	 recognition	 and	 protection	 against	 RNAses.	 Splicing,	 a	 process	 that	removes	 introns	 and	 joins	 exons	 together,	 also	 occurs	 in	 the	 nucleus,	 either	during	 or	 directly	 after	 transcription.	 Splicing	 allows	 for	 genes	 to	 express	different	isoforms,	which	can	create	different	proteins	products	(or	even	trigger	the	resulting	RNA	for	degradation).	Several	factors	regulate	RNA	splicing,	such	as	FUS.	 For	 example,	 the	 microtubule-associate	 protein	 Tau	 (MAPT)	 has	 six	alternative	 isoforms	expressed	 in	the	human	brain.	Alternative	splicing	of	exon	10	results	 in	isoforms	with	varied	amount	of	microtubule	binding	repeats.	This	alternative	splicing	is	thought	to	lead	to	tauopathies	seen	in	neurodegeneration	and	dementia.		Although,	most	alternative	splicing	is	not	pathological,	but	rather	is	 attuned	 to	 the	 cells	 needs.	 Depending	 on	 cell	 type	 or	 conditions,	 different	isoforms	 of	 the	 same	 protein	 may	 be	 required.	 For	 example,	 the	 alternative	splicing	 of	 the	 extracellular	 domain	 of	 the	 AMPA	 receptors	 yields	 to	 variants,	known	 as	 flip	 and	 flop	 (Pei	 et	 al.	 2009).	 In	 the	 case	 of	 GluR2,	 the	 flop	 variant	desensitizes	 faster	 than	 the	 flip	 variant,	 the	 two	variants	 also	display	different	kinetics.	In	this	case,	the	different	isoforms	tailor	synaptic	response.		An	 additional	 RNA	 editing	 variable,	more	 specific	 to	 neurons,	 is	 3’	 UTR	 length	and	composition.	Neuronal	mRNAs	frequently	possess	multiple	3’	UTR	isoforms,	this	 allows	 transcripts’	 localization	 and	 stability	 to	 be	 more	 highly	 regulated.	Transcripts	with	a	tendency	to	be	localized,	such	as	those	encoding	for	synaptic	or	neuritic	proteins,	tend	to	have	a	longer	3’	UTR	(Tushev	et	al.	2018).		
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3.2.	mRNP	Granules	and	Low	Complexity	Domains		Messenger	ribonucleoprotein	particles	(mRNPs)	are	defined	as	a	complex	of	RNA	binding	 proteins	 (RBPs)	 and	 mRNAs.	 Many	 mRNP	 components	 are	 added	 co-transcriptionally	and	aid	in	mRNA	splicing	(Moore	and	Proudfoot	2009).	As	the	mRNP	 exits	 the	 nucleus,	 some	 components	 are	 removed	while	 others,	 such	 as	FUS,	 may	 remain	 associated	 into	 the	 cytoplasm.	 Once	 in	 the	 cytoplasm,	 the	mRNPs	may	undergo	further	restructuring.	The	addition	and	removal	of	various	mRNP	 components	 determines	 the	 localization,	 stability	 and	 translation	 of	 the	RNA.	Some	mRNPs	need	to	be	delivered	to	particular	subcellular	regions,	such	as	axons	and	dendrites,	 for	 local	translation	(Doyle	and	Kiebler	2011).	 In	order	to	achieve	 this,	 particular	 components	 are	 necessary	 and	 the	 RNA	 must	 be	maintained	 in	 a	 translationally-repressed	 state.	 	 These	 translationally-inactive	RNPs	 are	 able	 to	 assemble	 into	 larger	 structures,	 called	 mRNP	 granules.	Examples	 of	 mRNP	 granules	 include:	 1)	 processing	 bodies	 (P-bodies;	 PB),	 2)	stress	granules	 (SGs),	3)	P	granules	 in	germ	cells,	and	 finally	4)	RNA	transport	granules	in	neurons,	also	called	RNA	granules.		While	all	of	these	granule	types	are	distinct,	they	have	several	things	in	common.	First,	 they	 transiently	 store	 silenced	mRNA	 for	 transport	 or	 storage	 (Erickson	and	Lykke-Andersen	2011;	Mitchell	and	Parker	2014).		Second,	they	are	dynamic	entities	 that	 interact	with	 each	 other	 (Kedersha	 et	 al.	 2005;	 Buchan,	Muhlrad,	and	 Parker	 2008).	 This	 interaction	 allows	 for	 exchange	 of	 some	 components,	such	as	G3BP.	G3BP	 is	a	key	component	of	 stress	granules	but	 is	also	 found	 in	neuronal	 transport	 granules	 (Atlas	 et	 al.	 2004).	 Additionally,	 several	 RNA	transport	 granule	 components,	 such	 as	 Staufen	 and	 Pumilio	 2,	 in	 response	 to	cellular	stress,	can	be	 found	 in	dendritic	SGs	(Thomas	et	al.	2005;	Vessey	et	al.	2006).	 These	 observations	 suggest	 that	 each	 granule	 type	 is	 not	 separate,	 but	rather	part	of	a	continuum	(Buchan	and	Parker	2009).		An	additional	and	important	similarity	between	different	mRNP	granules	 is	the	manner	in	which	they	are	assembled.	All	translationally-silenced	mRNP	granules	form	 by	 liquid-liquid	 demixing	 or	 liquid	 phase	 separation	 (LLPS)	 (Weber	 and	
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Brangwynne	 2012).	 mRNP	 granules	 behave	 like	 condensed	 liquid	 phases	 and	show	droplet-like	attributes,	 they	flow	when	in	a	streaming	fluid	and	fuse	with	one	 another	 to	 form	 larger	 droplets/granules	 (Patel	 et	 al.	 2015;	 Shin	 and	Brangwynne	2017)	giving	 them	their	dynamic	behavior.	The	weak	 interactions	between	 low	 complexity	 domains	 (LCDs)	 drive	 liquid-liquid	 demixing	 and	therefore	 formation	 of	mRNP	 granules	 (Holehouse	 and	 Pappu	 2015;	 Shin	 and	Brangwynne	2017).	LC	domains	are	naturally	disordered,	have	 low	amino	acid	diversity,	and	often	contain	repetitive	sequences	(J.	Wang	et	al.	2018;	Tompa	et	al.	 2014).	 TIA-1,	 as	 essential	 component	 of	 SG	 assembly,	 was	 the	 first	 protein	containing	an	LC	domain	demonstrated	 to	be	vital	 for	mRNP	granule	assembly	(Gilks	et	al.	2004).		LLPS	and	aggregation	of	FUS	are	 likely	 largely	driven	by	 the	N-terminal	SYGQ-rich	domain	and	occurs	in	a	concentration	dependent	manner	(Burke	et	al.	2015;	Kato	 et	 al.	 2012;	 Murakami	 et	 al.	 2015;	 Patel	 et	 al.	 2015;	 Z.	 Sun	 et	 al.	 2011).	Disease-associated	 mutations	 in	 FUS	 accelerate	 the	 transition	 between	 liquid	and	 solid	 state	 (Patel	 et	 al.	 2015).	 Additionally,	 it	 has	 been	 shown	 that	 the	 C-terminal	 RGG3-PY	 domain	 and	 the	 arginines	 are	 integral	 for	 phase	 separation	(Hofweber	 et	 al.	 2018).	 As	 formation	 of	 these	 solid	 state	 aggregates	 are	dependent	on	concentration,	it	is	easy	to	see	how	a	mutation	in	the	NLS,	causing	increased	 amounts	 of	 cytosolic	 FUS,	 would	 promote	 aggregation	 and	 aberrant	interactions.		 	Studies	have	shown	that	LC	domains	are	particularly	abundant	in	RBPs	linked	to	protein	 aggregation	 diseases,	 especially	 in	 FTD	 and	 ALS	 (J.	Wang	 et	 al.	 2018).	FUS	and	other	LC	domain	containing	RBPs	undergo	a	concentration-dependent	LLPS,	 and	 form	 liquid-like	 protein	 droplets.	 Over	 time	 FUS	 and	 other	 RBP	droplets	undergo	a	liquid-to-solid-phase	transition	resulting	in	the	formation	of	solid	condensates	(Molliex	et	al.	2015;	Patel	et	al.	2015;	Lin	et	al.	2015).	 	These	solid	 condensates	 are	much	 less	dynamic	 and	 inhibit	 exchange	of	 components,	thus	promoting	aggregation.		
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3.2.1.	Stress	Granules			Stress	granules	are	present	in	the	cytoplasm,	they	are	composed	of	poly	(A)	RNA	and	RNA	binding	proteins.	SGs	form	in	response	to	stress,	in	order	to	protect	the	cell;	 they	 sequester	 non-essential	 RNAs,	 allowing	 stress-protective	RNAs	 (such	as	 heat	 shock	 proteins)	 to	 be	 preferentially	 translated	 (Buchan,	 Capaldi,	 and	Parker	2012).	SGs	can	also	recruit	proteins,	such	as	those	involved	in	apoptosis	(thereby	 preventing	 cell	 death)	 and	 mTORC1,	 protecting	 the	 cells	 from	 DNA	damage	(Takahara	and	Maeda	2012).		Core	SG	components	include	the	48S	pre-initiation	complex,	PABP-1,	TIAR	and	G3BP	(Kedersha	et	al.	2005;	Anderson	and	Kedersha	 2006).	 The	 latter	 three	 proteins	 promote	 SG	 assembly	 and	 serve	 as	common	 SG	 markers.	 	 Under	 acute	 stress,	 elongating	 ribosomes	 run	 off	 the	mRNA	and	SG	nucleation	begins	by	the	recruitment	of	proteins	such	as	TIAR	and	G3BP	thus	promoting	the	aggregation	of	mRNPs	(Anderson	and	Kedersha	2008).	During	recovery	from	stress,	the	SG	proteins	dissociate,	allowing	progression	of	translation.			Several	ALS/FTD-associated	RBPs	are	 recruited	 to	SGs	 (e.g.	TDP-43,	FUS,	EWS,	TAF15,	 ATXN2,	 hnRNP	 A/B	 family)	 and	 some	 of	 them	 have	 been	 shown	 to	regulate	SG	dynamics	(Aulas	et	al.	2015).	Two	of	the	most	well-studied	RBPs	are	TDP-43	 and	 FUS.	 FUS	 knockdown	 or	 overexpression	 does	 not	 affect	 SG	formation,	 however	 TDP-43	 directly	 regulates	 G3BP	 levels	 (Aulas,	 Stabile,	 and	Vande	 Velde	 2012;	 Aulas	 et	 al.	 2015;	 Blechingberg	 et	 al.	 2012),	 therefore	affecting	SG-PB	 interactions.	Under	most	 stress	 conditions,	only	 small	 amounts	of	 TDP-43	 and	 FUS	 can	 be	 found	 in	 SGs,	 however,	 the	 hyperosmolar	 stressor	sorbitol	 induces	 a	 large	 cytosolic	 distribution	 and	 SG	 localization	 of	 both	wild	type	TDP-43	 and	FUS	 (Meyerowitz	 et	 al.	 2011;	 Sama	 et	 al.	 2013;	Walker	 et	 al.	2013).	Point	mutations	located	in	the	NLS	leading	to	cytosolic	mislocalization	of	both	 TDP-43	 and	 FUS	 strongly	 increase	 SG	 association	 (Dormann	 et	 al.	 2010;	Bentmann	 et	 al.	 2012)	 and	 were	 found	 to	 affect	 the	 binding	 of	 other	 SG-associated	 proteins	 such	 as	 TIA-1	 and	G3BP	 resulting	 in	 an	 increased	 number	and	size	of	SGs	(Baron	et	al.	2013;	Vance	et	al.	2013).	These	observations	suggest	that	 disease-associated	 mutations	 in	 the	 NLS	 of	 FUS	 cause	 aberrant	 protein	
	18	
interactions,	possibly	recruiting	additional	proteins	into	SGs,	resulting	in	altered	SG	size	and	dynamics.		High	 local	 concentrations	 of	 RBPs,	 such	 as	 FUS,	 in	 the	 cytoplasm,	 may	 cause	liquid-to-solid	 phase	 transition	 resulting	 in	 SG	 solidification,	 therefore	 forming	irreversible,	non-dynamic	aggregates	over	time	(Figure	3).	Evidence	supporting	this	has	been	shown	by	the	colocalization	of	SG	markers	with	pathological	FUS	inclusions	 in	 FTD	 and	 ALS	 patients	 (Fujita	 et	 al.	 2008;	 Bäumer	 et	 al.	 2010;	Dormann	 et	 al.	 2010).	 	 FUS	 proteinopathies	 are	 not	 the	 only	 examples	 of	pathological	 SGs:	 full-length	 TDP-43	 inclusions	were	 also	 shown	 to	 co-localize	with	the	SG	marker	PABP-1	(Bentmann	et	al.	2012;	Liu-Yesucevitz	et	al.	2010).	Additionally,	 FTD-Tau	 and	 Alzheimer’s	 patients	 show	 co-localization	 of	 SG	markers	and	Tau	aggregates	(Vanderweyde	et	al.	2012).			
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3.2.2.	RNA	Transport	Granules		Neurons	 are	 polarized	 cells,	 extending	 from	 the	 cell	 body	 are	 axons	 and	dendrites.	 Largely,	 the	 proteins	 present	 in	 the	 axon	 and	 dendrites	 are	synthesized	 in	 the	 cell	 body	 and	 transported	 into	 the	 neurites	 (Kennedy	 and	Ehlers	2006).	 Local	protein	 synthesis	 can	also	be	 triggered	 to	 take	place	along	the	axon	or	dendrites,	away	from	the	cell	body	(Hengst	and	Jaffrey	2007;	Doyle	
Figure	3:		LC	domain	driven	stress	granule	formation	and	pathological	
aggregate	formation	(adapted	from	(Bowden	and	Dormann	2016)).	In	response	to	cellular	stress,	mRNA	translation	is	paused	and	transcripts	and	inactive	mRNPs	are	transiently	sequestered	(step	1).	The	LC	domains	of	some	RBPs,	such	as	G3BP	and	TIA1	drive	this	formation.	FUS	may	be	sequestered	via	its	mRNA	targets.	Solidified	SGs	may	be	formed	by	LC	domain	driven	pathological	liquid-to-solid	phase	transition,	triggered	by	disease-associated	mutations	or	post-translational	modifications	(PTMs)	(step	2).		Finally,	this	may	lead	to	development	of	irreversible	RBP	aggregates	(step	3),	which	may	promote	neurodegeneration	by	sustained	translational	repression	and/or	trapping	of	RBPs.	Wiley-Blackwell	holds	the	copyright	(2016)	for	this	article	published	in	Journal	of	Neurochemistry	and	permits	the	usage	of	figures	in	this	dissertation.		
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and	Kiebler	2011).	 In	order	 for	 local	protein	synthesis	 to	occur,	 translationally	silenced	mRNAs	must	be	transported	via	RNA	transport	granules	into	axons	and	dendrites.	 In	 response	 to	 particular	 signals,	 the	 mRNAs	 can	 be	 released	 from	their	translationally	inactive	state	and	then	translated	into	protein.	Local	protein	synthesis	allows	 the	neuron	 to	amplify	specific	 signaling	pathways	quickly	and	acutely	in	a	location-specific	manner.	mRNA	transport	and	local	translation	has	been	visualized	for	several	transcripts	in	vitro	in	live	neurons,	some	of	the	first	transcripts	 imaged	were	 beta-actin	mRNA	bound	by	 ZBP1	 (Buxbaum,	Wu,	 and	Singer	2014;	H.	Y.	Park	et	al.	2014).		Neuronal	 RNA	 granules	 have	 been	 extensively	 purified	 and	 studied.	 The	 first	indication	 that	 the	 bound	 mRNAs	 are	 in	 a	 translationally	 inactive	 state	 came	from	a	cell	fractionation	followed	by	sucrose	gradient	from	cultured	rat	neurons.	The	 authors	 found	 that	 while	 the	 granules	 were	 enriched	 in	 ribosomes	 and	Staufen,	they	lacked	eIF4E,	eIF4G	and	tRNAs	(Krichevsky	and	Kosik	2001).	A	few	years	 later,	 Kanai	 and	 colleagues	 isolated	 a	 large	 detergent-resistant,	 RNase-sensitive	granule	from	mouse	brain	found	to	bind	mouse	kinesin	(KIF5).		Most	of	the	 major	 protein	 components	 were	 found	 to	 be	 RBPs:	 Pur-alpha,	 hnRNP-U,	PSF/Splicing	factor	proline/glutamine-rich	(SFPQ)	and	Staufen	1,	all	of	which	are	vital	for	CamKIIalpha	mRNA	dendritic	localization.		FUS	was	also	identified	as	a	major	 component	 of	 neuronal	 RNA	 granules	 (Kanai,	 Dohmae,	 and	 Hirokawa	2004).		mRNA	localization	and	translation	play	an	essential	role	in	axonal	path	finding	in	the	 developing	 nervous	 system.	 Axons	 are	 guided	 to	 their	 final	 destination	through	 the	plasticity	of	 their	 growth	 cones	enabled	by	 local	protein	 synthesis	(Hengst	 and	 Jaffrey	 2007).	 Local	 translation	 in	 axons	 seems	 to	 be	 primarily	occurring	 in	 developing	 axons,	 however	 nerve	 injury	 or	 neurodegeneration	results	 in	 the	 reappearance	 of	 machinery	 necessary	 for	 local	 translation	(Baleriola	et	al.	2015).		This	may	also	occur	in	FTD/ALS	patients,	as	both	TDP-43	and	FUS	have	been	identified	at	pre-synaptic	sites	of	axon	terminals	in	neurons	(Narayanan	et	al.	2013;	Schoen	et	al.	2015).		
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In	 the	 mature	 CNS,	 local	 translation	 is	 important	 in	 dendritic	 spines.	 Upon	neuronal	stimulation,	dendritic	spines	can	be	removed,	morphologically	altered	or	 new	 spines	 can	 appear	 (Lang	 et	 al.	 2004).	 	 Activity-induced	 local	 protein	synthesis	 at	 synapses	 contributes	 to	 these	 changes	 and	 is	 crucial	 for	 synaptic	plasticity,	 the	cellular	basis	 for	 learning	and	memory	 (Doyle	and	Kiebler	2011;	Puthanveettil	et	al.	2008).	Local	 translation	begins	with	 the	binding	of	RBPs	 to	cis-acting	localization	elements,	usually	located	in	the	3’UTR	(Doyle	and	Kiebler	2011).	Largely	occurring	in	the	nucleus,	RBPs	come	into	contact	with	the	native	transcripts	 and	 mRNPs	 are	 assembled.	 The	 mRNP	 is	 then	 exported	 from	 the	nucleus	to	the	cytoplasm,	where	additional	RBPs,	such	as	Staufen,	can	bind	and	remodel	 them.	 These	 mRNPs,	 in	 a	 translationally	 repressed	 state,	 are	 then	assembled	 into	 larger	granules,	known	as	RNA	transport	granules	(Kiebler	and	Bassell	2006;	Mitchell	and	Parker	2014).	Subsequently,	molecular	motors,	such	as	kinesins,	are	recruited	to	the	granules	and	transport	them	along	microtubules	to	 their	 final	 destination	 (Hirokawa	 2006).	 RNA	 transport	 granules	 are	 then	anchored	 at	 or	 near	 synapses	 or	 they	 cruise	 back	 and	 forth	 within	 dendrites	awaiting	 a	 signal	 (Bramham	 and	Wells	 2007;	 Doyle	 and	 Kiebler	 2011).	 In	 the	final	 step,	 upon	 synaptic	 activation,	mRNPs	 are	 recruited	 into	 dendritic	 spines	via	actin	filaments	or	microtubules	(Yoshimura	et	al.	2006;	Jaworski	et	al.	2009).		The	 transcripts	 are	 then	 released	 from	 the	 mRNPs	 for	 translation	 to	 occur	(Hüttelmaier	et	al.	2005).	The	mechanism	by	which	these	mRNAs	are	released	in	not	 yet	 completely	 understood.	 Post-translational	 modification	 of	 RBPs	(Ostareck-Lederer	et	al.	2002;	Hüttelmaier	et	al.	2005)	or	a	prion-like	switch	in	protein	 conformation,	 as	 what	 occurs	 with	 CPEB	 and	 its	 Drosophila	 homolog	Orb2	(Si	et	al.	2010;	Khan	et	al.	2015),	are	 two	possible	explanations	as	 to	 the	mechanism.		
3.3.	The	Role	of	FUS	in	RNA	Processing	in	Neurons		FUS	 is	 a	 primarily	 nuclear	 protein,	 where	 it	 tends	 to	 bind	 long	 introns	 and	regulate	splicing	(Polymenidou	et	al.	2011;	Ishigaki	et	al.	2012;	Lagier-Tourenne	et	al.	2012;	Rogelj	et	al.	2012;	Zhou	et	al.	2013)	as	well	as	regulate	transcription	by	 binding	 to	 promoters	 (Tan	 et	 al.	 2012;	 Yang	 et	 al.	 2014).	Due	 to	 its	 largely	
	22	
nuclear	 presence,	 its	 cytosolic	 roles	 have	 been	 poorly	 studied	 until	 more	recently.	 Using	 super-resolution	 microscopy,	 Schoen	 and	 colleagues	 recently	found	that	FUS	is	also	present	in	axon	terminals	of	mature	hippocampal	neurons,	very	 closely	 localized	 to	 synaptophysin,	 a	 pre-synaptic	 vesicle	 protein,	 and	adjacent	to	the	active	zone	protein,	Bassoon	(Schoen	et	al.	2015).	Although	these	findings	 are	 still	 preliminary,	 they	 imply	 that	 FUS	may	 play	more	 of	 a	 role	 in	axons	 than	previously	 thought,	 and	 that	 further	 investigation	of	 this	 important	issue	is	warranted.		Even	more	evidence	suggests	 there	 is	a	vital	role	 for	FUS	 in	dendrites.	FUS	has	been	 identified	 in	 somatic	 and	 dendritic	 punctae	 (Belly	 et	 al.	 2005;	 Fujii	 et	 al.	2005).	 	 In	 both	 human	 and	 mice,	 FUS-positive	 neuropil	 granules	 have	 been	identified	 in	MAP2-positive	 dendrites	 in	 the	 cortex,	 brainstem	 and	 spinal	 cord	(Aoki	et	al.	2012).	Upon	synaptosomal	fractionation	FUS	can	be	detected	mostly	in	 the	 post-synaptic	 density	 (PSD)	 fraction.	 In	 hippocampal	 neurons,	 FUS	 is	found	in	dendrites	and	occasionally	in	PSD95-positive	dendritic	spines	(Belly	et	al.	 2005;	 Fujii	 et	 al.	 2005).	 These	 FUS-positive	 dendritic	 granules	 show	bidirectional	movement,	 but	within	 spines	 become	 stationary.	 This	movement	can	 be	 abolished	 with	 actin	 or	 microtubule	 destabilizing	 compounds	 (Fujii	2005).	 The	 kinesin,	 KIF5,	 a	 microtubule	motor	 protein,	 binds	 directly	 to	 FUS-containing	 granules	 and	 transports	 them	 along	 microtubules	 (Kanai,	 Dohmae,	and	 Hirokawa	 2004).	 Myosin-Va,	 an	 actin	 based	 motor	 protein	 delivers	 FUS	further	into	the	dendritic	spines	(Yoshimura	et	al.	2006).		There	is	mounting	evidence	that	neuronal	stimulation	recruits	FUS	into	dendritic	spines.	 Treatment	 of	 mouse	 hippocampal	 neurons	 with	 3,5-dihydroxyphenylglycine	 (DHPG),	 a	 group	 I	mGluR	 agonist,	 causes	 FUS-positive	granules	in	dendrites	and	dendritic	spines	to	increase,	while	other	post-synaptic	proteins	 (PSD95,	 Homer-1c	 and	 Shank)	 remain	 unchanged	 (Fujii	 et	 al.	 2005).	Using	 a	 combination	 of	 a	 chemically-induced	 long-term	 potentiation	 (cLTP)	protocol	 combined	 with	 BDNF	 to	 stimulate	 rat	 cortical	 neurons	 led	 to	 an	increase	 in	 several	 RBPs,	 including	 FUS,	 in	 the	 postsynaptic	 densities	 (Zhang,	Neubert,	 and	 Jordan	 2012).	 Additionally,	 FUS	 has	 been	 found	 to	 be	 associated	
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with	 N-methyl-D-aspartate	 (NMDA)	 receptor	 complexes	 isolated	 from	 mouse	brain	(Husi	et	al.	2000).		FUS	 is	 a	known	RNA	binding	protein,	 it	 is	present	 in	neurites	 and	 responds	 to	dendritic	 stimulation.	But	what	 about	 its	RNA	 targets	 in	neurons?	The	Takumi	lab	has	shown	that	Nd1-L	mRNA,	which	encodes	for	an	actin	stabilizing	protein,	co-immunoprecipitates	 with	 FUS.	 In	 neurons	 treated	 with	 DHPG,	 there	 is	 an	increase	 in	 β-actin	 and	 Nd1-L	 mRNA	 in	 dendrites.	 This	 activity-dependent	recruitment	 of	Nd1-L	 mRNA	 into	 dendrites	 is	 lost	 in	 FUS	 knockout	 mice	 and	further	 rescued	upon	re-expression	of	FUS.	Primary	cortical	neurons	 from	FUS	knockout	 mice	 not	 only	 have	 a	 decrease	 in	 the	 number	 of	 spines,	 but	 also	decrease	 in	 the	 ratio	 of	 mature	 to	 immature	 spines.	 This	 dendritic	 spine	abnormality	 can	be	 rescued	by	over-expression	of	Nd1-L.	Thus,	one	manner	 in	which	FUS	may	regulate	spine	morphology	and	synaptic	transmission	is	through	the	delivery	of	Nd1-L	mRNA	to	synapses	(Fujii	2005).	Furthermore,	a	dominant	negative	 mutant	 or	 knockdown	 of	 myosin	 Va	 inhibits	 activity-dependent	 FUS	relocalization,	 demonstrating	 this	 relocalization	 is	 mediated	 by	 the	 actin	cytoskeleton	(Yoshimura	et	al.	2006).			Not	 only	 has	 FUS	 been	 shown	 to	mediate	 RNA	 transport,	 but	 it	 has	 also	 been	shown	 to	 stabilize	 some	 of	 its	 mRNA	 targets.	 Examples	 of	 such	 are	 GluA1,	 a	glutamate	 receptor,	 and	 SynGAP	 α2,	 a	 protein	 essential	 for	 spine	 maturation	(Udagawa	et	al.	2015;	Yokoi	et	al.	2017).	GluA1	mRNA	encodes	for	a	subunit	of	alpha	amino-3-hydroy-5-mythylisoxazole-4-propionate	(AMPA)	receptors	and	is	vital	for	spine	maturation	and	synaptic	transmission.	FUS	binds	the	GluA1	3’	UTR	and,	by	controlling	poly(A)-tail	 length,	FUS	regulates	 its	stability	 in	 the	cytosol.	Knockdown	 of	 FUS,	 by	 introduction	 of	 FUS	 shRNA	 in	 the	 mature	 mouse	hippocampus	 in	vivo,	 results	 in	a	decrease	 in	mature	spines	and	an	 increase	 in	filopodia-like	 spines.	 This	 causes	 a	 change	 in	 synaptic	 transmission	 of	hippocampal	 neurons	 and	 FTD-like	 behavioral	 abnormalities,	 including	disinhibition,	 hyperactivity	 and	 social	 interaction	 defect.	 These	 cellular	 and	behavioral	defects	can	partially	be	attributed	to	down-regulation	of	GluA1	mRNA	and	 protein	 levels	 resulting	 from	 the	 knockdown	 of	 FUS.	 	 Re-expression	 of	
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GluA1,	in	the	context	of	a	FUS	knockdown,	rescues	synaptic	transmission,	spine	maturation	 defects	 and	 some	 of	 the	 behavioral	 abnormalities	 (Udagawa	 et	 al.	2015).		Synaptic	Ras	GTPase-activating	protein	1	(SynGAP1)	 is	a	Ras	activating	protein	critical	 for	 cognition	 and	 synapse	 function,	 localizing	 to	 the	 PSD,	 it	 negatively	regulates	 the	Ras/Rap	pathway	(Kim	et	al.	1998;	Carlisle	et	al.	2008;	 Jeyabalan	and	Clement	2016)		and	has	previously	been	shown	to	be	associated	with	autism	spectrum	disorders	and	epilepsy	(Mignot	et	al.	2016).	Heterozygous	knockout	of	SynGAP	 in	mice	causes	an	 increase	 in	 the	number	of	mature	spines	 (Kim	et	al.	2003;	 Clement	 et	 al.	 2012;	 C.-C.	 Wang,	 Held,	 and	 Hall	 2013).	 However,	 it	 is	important	 to	 note	 that	 there	 are	 several	 isoforms	 of	 SynGAP	 with	 opposing	effects	 on	 synaptic	 transmission.	 For	 example,	 SynGAP	 α1	 overexpression	decreases	 mEPSC	 amplitude,	 whereas	 SynGAP	 α2	 overexpression	 increases	mEPSC	 amplitude	 (McMahon	 et	 al.	 2012).	 The	 inclusion	 of	 exon	 19	 in	 the	 α1	isoform	 causes	 a	 frameshift	 mutation	 resulting	 not	 only	 in	 a	 shorter	 protein	product	than	that	of	α2,	but	also	a	longer	3’UTR	in	α2.	It	is	this	longer	3’UTR	of	SynGAP	 α2	 that	 has	 been	 shown	 to	 be	 bound	 by	 FUS.	 In	 conjunction	 with	ELAVL4,	 FUS	 mediates	 stable	 SynGAP	 α2	 mRNA	 expression,	 in	 the	 absence	 of	FUS,	 ELAVL1	 binds	 and	 SynGAP	 α2	 mRNA	 is	 destabilized	 and	 degraded.	 FUS	knockout	 mice	 have	 decreased	 levels	 of	 SynGAP	 α2	 and	 supplementation	 of	SynGAP	α2	ameliorates	the	behavioral	abnormalities	seen	in	FUS	knockout	mice	(Yokoi	et	al.	2017).		Thus,	 some	 of	 the	 identified	 mRNA	 targets	 of	 FUS,	 such	 as	 Nd1-L,	 GluA1	 and	SynGAPα2,	 are	 all	 major	 players	 in	 dendritic	 spine	 dynamics.	 Therefore	alteration	of	FUS	levels,	either	by	knockdown	or	overexpression	can	affect	spine	morphology	and	synaptic	transmission.	A	summary	of	its	role	in	neurons	can	be	seen	in	Figure	4	(Bowden	and	Dormann	2016).				
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4.	FUS-ALS	Mouse	Models		ALS-associated	FUS	mutations,	 resulting	 in	higher	concentrations	of	FUS	 in	 the	cytosol	 (Dormann	 and	Haass	 2013),	 also	 cause	 aberrant	 dendritic	morphology	and	changes	in	local	protein	synthesis	in	dendrites.	Several	mouse	models	have	been	created	and	demonstrate	 this	aberrant	 local	proteome,	 spine	morphology	and	synaptic	transmission.		Transgenic	mice	expressing	human	FUS-R521G	show	reduced	dendritic	arbors	and	mature	spines	compared	to	non-transgenic	or	FUS-WT	mice	(Sephton	et	al.	2014).		More	 recently,	 the	 Shneider	 lab	 created	 three	 mouse	 lines	 expressing	 human	FUS:	 wild	 type,	 R521C	 and	 P525L	 from	 the	MAPT	 locus.	 Although	 the	 mRNA	levels	are	equal,	mutant	FUS	protein	is	expressed	at	higher	levels	than	FUS	wild	
Figure	4:	The	physiological	role	of	FUS	in	neuritic	mRNA	metabolism	(modified	from	(Bowden	and	Dormann	2016))11.	FUS	regulates	splicing	of	Tau	mRNA	and	transports	the	mRNA	of	Nd1-L	into	dendrites.	FUS	also	regulates	the	stability	of	GluA1	mRNA.	Impaired	synaptic	function	may	occur	upon	misregulation	of	these	targets.	Wiley-Blackwell	holds	the	copyright	(2016)	for	this	article	published	in	Journal	of	Neurochemistry	and	permits	the	usage	of	figures	in	this	dissertation.		
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type	in	the	brain	and	spinal	cords	of	the	mice.	FUS	was	found	to	be	cytosolically	mislocalized	 and	 all	 Tau-expressing	 cells	 underwent	 progressive	 degeneration.	Both	 mutant	 lines	 also	 experienced	 progressive	 and	 early	 degeneration	 of	neuromuscular	 junctions	 (NMJs.)	 Postnatal	 knockout	 of	 endogenous	 FUS	 from	motor	neurons	confirmed	that	it	was	not	simply	loss	of	function	that	resulted	in	motor	degeneration	(Sharma	et	al.	2016).		In	 2017,	 the	 Fisher	 lab	 created	 the	 FUSDelta14	 mouse	 model	 in	 which	 they	introduced	a	human	frameshift	mutation	in	the	mouse	FUS	locus.	This	frameshift	mutation	causes	the	skipping	of	exon	14	and	out	of	frame	translation	of	exon	15.		Heterozygous	FUSDelta14	mice	were	found	to	have	diffuse	nuclear	and	cytosolic	FUS	 staining	 (without	 complete	 depletion	 of	 FUS	 from	 the	 nucleus),	 RNA	expression	 changes,	 progressive	 motor,	 NMJ	 and	 motor	 neuron	 degeneration	(Devoy	et	al.	2017).		The	Dupuis	lab	created	the	mouse	model	utilized	for	these	studies.	A	mutant	FUS	mouse	line,	FusΔNLS,	was	made	by	removing	the	NLS	from	endogenous	FUS.	Using	homologous	recombination,	 they	 inserted	a	 floxed	stop	cassette	 following	exon	14,	preventing	transcription	of	the	NLS-encoding	exon	15	(Scekic-Zahirovic	et	al.	2016).	The	FusΔNLS	mice	show	a	dramatic	relocalization	of	FUS	from	the	nucleus	to	the	cytosol,	resulting	in	RNA	expression	changes,	motor	neuron	loss,	as	well	as	aberrant	protein	localization.	Mice	homozygous	for	FusΔNLS	die	upon	birth	due	to	respiratory	 insufficiency.	 Heterozygous	 (FusΔNLS/+)	 mice	 demonstrate	hyperactive	 behavior	 around	 1-2	 months	 of	 age,	 further	 behavioral	 defects	(primarily	 in	 social	 interaction)	 are	 evident	 around	 4	months	 of	 age.	 FusΔNLS/+	mice	do	not	show	an	overt	motor	phenotype	until	approximately	10	months	of	age,	which	is	accompanied	by	brain	atrophy.	By	22	months,	the	motor	deficit	 is	more	 pronounced	 as	 observed	 in	 tasks	 such	 as	 the	 inverted	 grid	 and	 catwalk.	Electromyography	and	ChAT	immunohistochemistry	reveal	denervation	of	NMJs	and	 degeneration	 of	 motor	 neurons.	 The	 FusΔNLS/+	 mice	 seem	 to	 recapitulate	early	stages	of	ALS,	although	 they	do	not	have	cytosolic	FUS	or	p62	 inclusions,	but	 they	 do	 have	 significant	 ubiquitin	 pathology.	 The	 resulting	molecular	 and	behavioral	phenotype	appears	to	be	a	result	of	a	gain	of	cytosolic	function	of	FUS,	
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rather	than	a	loss	of	nuclear	function	of	FUS.	Reversal	of	the	FusΔNLS	mutation	(by	expression	 of	 Cre	 recombinase)	 in	 motor	 neurons	 prevents	 motor	 neuron	degeneration	 and	 delays	 motor	 deficits,	 implying	 both	 a	 cell	 autonomous	 and	non-cell	 autonomous	mechanism	of	degeneration	 (Scekic-Zahirovic	et	 al.	2017;	Scekic-Zahirovic	et	al.	2016).			
5.	Aims	of	this	thesis		As	the	cytosolic	and	neuritic	roles	of	FUS	are	not	yet	fully	understood,	I	decided	to	unravel	the	FUS	cytosolic	interactome,	both	on	an	RNA	and	protein	level	and	examine	how	 these	 interactions	 are	 altered	by	ALS-associated	mutations.	 	 It	 is	clear	from	preliminary	studies	of	the	cytosolic	targets	of	FUS,	that	its	role	in	the	cytosol	 and	 processes	 is	 vital.	 	 In	 disease,	 FUS	 can	 be	 found	 in	 cytosolic	aggregates,	 thereby	 removing	 FUS	 from	 its	 normal	 duties.	 In	 addition	 to	 the	nuclear	loss	of	function,	perhaps	there	is	a	toxic	cytosolic	gain	of	function.	More	specifically,	 some	 protein	 interactors	 may	 be	 lost	 or	 gained,	 altering	 RNP	composition.	 This	 altered	 RNP	 composition,	 in	 combination	 with	 altered	 RNA	target	binding	may	result	in	disturbed	cytosolic	mRNA	processing.		In	 order	 to	 evaluate	 the	 effect	 of	 disease-associated	 mutations	 on	 the	 FUS	interactome	and	downstream	processes,	we	obtained	 the	FusΔNLS	mouse	model	described	above.	Using	the	heterozygous	FusΔNLS/+	mice	I	aimed	to:		(i)	purify	cytosolic	FUS	mRNP	complexes	from	the	cortices	of	FusΔNLS/+	mice,			(ii)	identify	RNA	and	protein	interactors	of	FUS,		(iii)	 identify	 the	 differentially	 bound	 RNA	 targets	 and	 protein	 interactors	between	FUS	WT	and	FusΔNLS	mice	and	finally		(iv)	confirm	some	of	the	significantly	different	interactors	in	cell	culture.		I	hypothesize	that	abnormal	cytosolic	localization	of	FUS	causes	both	a	toxic	gain	and	loss	of	function	in	its	interactions	with	targets	and	other	proteins.		 	
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II.	RESULTS		
DECLARATION	OF	CONTRIBUTIONS			cDNA	library	preparation	and	RNA	Sequencing	was	performed	by	Laboratory	for	Functional	 Genome	 Analysis	 (LAFUGA)	 at	 the	 Gene	 Center	 Munich.	 RNA	Sequencing	Analysis	was	performed	 in	 collaboration	with	Tobias	 Straub	of	 the	Biomedical	Center,	LMU.	Stephan	Mueller	of	the	Lichtenthaler	lab,	DZNE	Munich,	performed	 the	 Mass	 Spectrometry	 and	 requisite	 sample	 preparation	 and	prepared	Figure	33.		
1.	Establishment	of	FUS	RNP	granule	isolation	from	mouse	brain		To	properly	evaluate	changes	in	the	FUS	interactome	in	wild	type	versus	mutant	mice,	 I	 first	 needed	 to	 establish	 a	 protocol	 to	 enrich	 for	 the	 cytosolic	compartment	of	mouse	cortex	and	then	immunoprecipitate	(IP)	FUS	with	a	high	degree	 of	 specificity.	 Therefore,	 I	 began	 by	 testing	 different	 FUS	 antibodies	 in	both	native	and	denaturing	conditions.	The	final	workflow	of	the	procedure	can	be	seen	Figure	5.		
		
Figure	5:	Schematic	of	the	optimized	workflow	for	isolating	cytosolic	FUS-
RNPs	from	mouse	cortex.	Following	hypotonic	lysis,	the	cytosolic	fraction	of	mouse	cortices	was	centrifuged	at	14,000	x	g	to	remove	heavier	membrane	components	and	debris.	The	samples	were	then	IP’d	with	a	FUS	antibody	or	mouse	IgG,	both	of	which	were	covalently-crosslinked	to	magnetic	beads.	Following	washes	in	the	same	buffer,	the	samples	were	eluted	with	2x	Laemmli	(for	SDS-PAGE	and	MS	analysis)	or	Trizol	(for	RNA-sequencing).	
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1.1.	FUS	Antibody	Testing		In	order	to	analyze	FUS	localization	properly,	I	first	needed	to	confirm	antibody	specificity.	A	table	of	the	antibodies	used	throughout	this	thesis	 is	presented	in	Table	1.		
	
		I	first	began	by	confirming	FUS	reactivity	in	western	blot	(Figure	6).	I	tested	the	following	 antibodies:	 Santa	 Cruz	 anti-FUS	 4H11	 (mouse),	 Bethyl	 A300-302	(rabbit),	 and	 two	 home-made	 antibodies	 from	 a	 collaborator,	 one	 produced	 in	mouse	 (19B2)	and	one	produced	 in	 rabbit.	 I	performed	subcellular	 fraction	on	mouse	 brain	 and	 ran	 the	 cytosolic	 and	 nuclear	 fractions	 on	 an	 SDS-PAGE	followed	by	western	blot.		While	the	molecular	weight	of	Fus	is	approximately	55	kD,	 it	usually	runs	around	75	kD	on	SDS-PAGE.	While	all	 tested	antibodies	had	the	appropriate-sized	band	present	at	approximately	75	kD,	the	two	home-made	
Antibody	 Company	 Epitope	 Species	 Application	Specificity	4H11	 Santa	Cruz	 C-terminus,	 but	 N-terminal	of	aa.	466	 Mouse	 IF,	WB,	IP	A300-302	 Bethyl	 N-terminus	(aa.	1-50)	 Rabbit	 IF,	WB	A300-294	 Bethyl	 far	 C-terminus	 (aa.	 500	 –	526)	 Rabbit	 WB,	IP	19B2	 Ruepp	Lab	 middle		 Mouse	 IF,	WB	Ruepp	Lab	 Ruepp	Lab	 	N-terminus	(aa.	1-286)	 Rabbit	 WB	11570-1-AP	 Proteintech	 N-terminus	 Rabbit	 	ab70381	 Abcam	 	C-terminus	(a.a.	400-450)	 Rabbit	 	
9G6	
Helmholtz	Antibody	Core	Facility	 Asymm.	 Dimethylated	 FUS-RGG3	 domain	 (aa.	 473	 –	503)	 Rat	
Table	1:	FUS	antibodies	used	throughout	this	thesis.	The	antibody	name/catalog	number,	along	with	the	source,	epitope	and	species	in	which	it	was	produced	are	listed.	Applications	in	which	each	antibody	was	found	to	be	FUS-specific	are	listed	under	application	specificity.		
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antibodies	 from	 a	 collaborator	 had	 additional	 bands,	 suggesting	 nonspecific	reactivity.											
	To	further	confirm	antibody	specificity,	I	stained	two	different	human	cell	lines,	HeLa	and	SH-SY5Y,	for	which	we	had	a	FUS	knockout	(KO)	line	available	from	a	collaborator	(Dr.	Marc-David	Ruepp).	 In	the	first	test,	 I	stained	for	FUS	in	HeLa	FUS	KO	and	in	the	parental	wild	type	cell	line	(Figure	7).	Santa	Cruz	4H11,	19B2	and	Bethyl	302	all	showed	a	strong	nuclear	staining	in	the	wild	type	cells	with	a	very	weak	background	staining	in	the	Fus	KO	line.	While	the	Abcam,	Bethyl	294	and	9G6	antibodies	also	 showed	a	nuclear	 staining,	 the	 staining	 in	 the	FUS	KO	line	had	much	higher	background.	 I	 found	 that	 the	4H11	 (Santa	Cruz)	 and	 the	A300-302	(Bethyl)	had	satisfactory	signal	to	noise	ratios.						
 
Figure	6:	Testing	of	FUS	antibodies,	Santa	Cruz	4H11,	Bethyl	302,	Ruepp	Lab	
19B2	and	Ruepp	Lab	Rabbit	by	western	blot	on	fractionated	mouse	brain.	All	antibodies	show	bands	at	the	correct	size,	although	some	show	more	background	bands	than	others. 	
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	As	 every	 cell	 type	 is	 different	 and	 as	 I	 would	 ultimately	 like	 to	 stain	 primary	neuronal	cultures,		I	proceeded	to	examine	FUS	antibody	reactivity	in	the	human	neuronal-like	 SH-SY5Y	 cell	 line.	 As	 demonstrated	 in	 Figure	 8,	 all	 antibodies,	
Figure	7:	Immunostaining	in	HeLa	WT	or	FUS	KO	with	different	FUS	
antibodies:		A.	Santa	Cruz	4H11	(1:1000),	B.	Abcam	(1:500),	C.	Bethyl	A300-302	(1:500),	D.	Ruepp	Lab	19B2	(1:1000),	E.	Bethyl	A300-294	(1:500)	and	F.	9G6	(1:2).	Cells	were	fixed	in	4%	formaldehyde	and	permeabilized	with	0.5%	Triton	in	PBS.	Blocking	and	antibody	incubations	were	performed	in	5%	milk	in	PBS-Tween	(T).	All	washes	were	done	with	PBS-T.	
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excluding	 11570-1-AP	 (Proteintech)	 produced	 a	 FUS-specific	 signal	 in	 the	parental	SH-SY5Y	cell	line	compared	to	the	FUS	KO	line.		
	
		
	
Figure	8:	Staining	of	FUS	in	either	WT	or	FUS	KO	SH-SY5Y	cells	using	A.	Proteintech	(PTG)	11570-1-AP	(1:500),	B.	Bethyl	A300-294	(1:500),	C.	Bethyl	A300-302	(1:500),	D.	Santa	Cruz	4H11	(1:1000)	or	E.	Ruepp	Lab	19B2	(1:1000).	Cells	were	fixed	in	4%	formaldehyde	and	permeabilized	with	0.5%	Triton	in	PBS.	Blocking	and	antibody	incubations	were	performed	in	5%	milk	in	PBS-Tween	(T).	All	washes	were	done	with	PBS-T.		
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1.2.	Fractionation	of	mouse	cortex	into	nuclear	and	cytosolic	fraction		As	 the	 aim	 of	 this	 these	 is	 to	 identify	 differential	 cytosolic	 FUS	 protein	interactors,	following	initial	antibody	tests,	the	next	step	is	then	to	optimize	the	subcellular	 fraction	 protocol	 (Figure	 9).	 	 I	 initially	 tried	 various	 HEPES-based	buffers	and	cytosolic	fractionation	kits	(NE-PER	from	Invitrogen)	but	found	high	amounts	of	the	nuclear	contamination	in	the	cytosolic	fraction.	I	eventually	tried	a	 classical	 hypotonic	 lysis	 buffer	 without	 detergent,	 which	 causes	 the	 cells	 to	swell,	and	then	rupture	them.		The	initial	basic	workflow	of	the	nuclear/cytosolic	fractionation	can	be	seen	in	Figure	9.	
	
		FUS	is	mostly	nuclear	and	only	small	amounts	of	FUS	are	present	in	the	cytosol	under	physiological	conditions	(Scekic-Zahirovic	et	al.	2017).	Therefore,	the	next	step	after	obtaining	a	cytosolic	fraction	was	to	confirm	that	FUS	is	in	fact	present	at	 detectable	 levels	 for	 further	 enrichment	 by	 immunoprecipitation.	 Western	blotting	demonstrated	that	FUS	is	present	at	expected	ratios	between	the	cytosol	and	nucleus	 (Figure	10).	Antibodies	 against	 histone	H3,	 a	 nuclear	marker,	 and	GAPDH,	 a	 cytosolic	marker,	 were	 used	 to	 confirm	 enrichment	 of	 the	 cytosolic	fraction.	Although	 there	 is	 some	GAPDH	contamination	 in	 the	nuclear	 fraction,	
Figure	9:	The	initial	subcellular	fractionation	workflow.	Cortices	from	young	adult	mice	were	removed	and	flash	frozen.	Immediately	upon	removal	of	cortices	from	the	-80°C	freezer,	cortices	were	put	into	a	dounce	homogenizer	with	hypotonic	buffer	(10	mM	HEPES	pH	7.9,	10	mM	KCl,	1.5	mM	MgCl2	and	protease	inhibitor).	Brains	were	gently	dounced	and	then	left	on	ice	for	10	minutes.	Following	this	incubation,	the	suspension	was	then	either	vortexed	or	dounced	again,	followed	by	centrifugation	at	3,000	x	g	for	10	minutes.	The	supernatant	was	collected	as	the	cytosolic	fraction	(purple)	and	pellet	as	the	nuclear	fraction	(blue).		
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likely	 representing	 unbroken	 cells,	 the	 cytosolic	 fraction	 is	 clear	 of	 obvious	nuclear	contamination.										
	
1.3.	Optimization	of	FUS	Immunoprecipitation	Procedure		
1.3.1.	Testing	different	FUS	antibodies	in	immunoprecipitation		As	previously	shown,	we	have	several	FUS-specific	antibodies	to	detect	FUS	by	IF	or	 Western	 blot	 (see	 Table	 1	 above).	 I	 next	 wanted	 to	 test	 which	 of	 these	antibodies	also	was	suitable	for	immunoprecipitation	(IP)	of	FUS.		As	the	nuclear	fraction	contains	much	more	FUS	than	the	cytosolic	fraction,	I	 initially	used	the	nuclear	fraction	of	mouse	brain	to	test	the	different	antibodies	in	IP.	I	first	tested	three	rabbit	polyclonal	antibodies	(two	from	Bethyl	Labs	and	a	third	made	by	the	Ruepp	Lab)	bound	to	Sepharose	A	beads	performed	the	immunoprecipitation	in	hypertonic	 buffer	 (10	mM	HEPES,	 pH	7.9,	 10	mM	KCl,	 1.5	mM	MgCl2,	 150	mM	NaCl,	 0.5%	 NP-40,	 protease	 inhibitor)	 plus	 10%	 glycerol.	 After	 3	 washes	 in	hypertonic	buffer,	I	eluted	bound	protein	by	boiling	in	2x	Laemmli	buffer.			
Figure	10:	Successful	Subcellular	Fraction	of	wild	type	mouse	brain.	Following	subcellular	fractionation,	fractions	were	immunoblotted	FUS	(4H11),	Histone	H3	(Abcam),	to	identify	nuclear	enrichment	and	depletion	from	the	cytosolic	fraction	and	GAPDH	(Helmholtz)	as	a	cytosolic	marker.	The	blot	shows	a	nice	cytosolic	enrichment.	
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		As	shown	in	Figure	11A,	the	A300-294	antibody	from	Bethyl	appeared	to	work	best	to	immunoprecipiate	FUS	under	these	conditions,	while	no	efficient	IP	was	seen	 for	 Bethyl	 antibody	A300-302	 and	 the	Ruepp	 lab	 rabbit	 antibody.	Next,	 I	tested	 the	 Bethyl	 A300-294	 antibody	 in	 the	 cytosolic	 brain	 fraction,	 which	contains	lower	amounts	of	FUS	than	the	nuclear	fraction.	The	IP	of	FUS	from	the	cytosolic	 fraction	 with	 A300-294	 also	 worked	 well	 with	 the	 above-described	protocol	(Figure	11B).		In	 addition,	 I	 tested	 the	 Proteintech	 rabbit	 antibody	 (11570-1-AP)	 which	recognizes	 the	N-terminus	 of	 FUS	 (Figure	12).	 Although	 the	 rabbit	 IgG	 yielded	background	FUS	binding,	the	antibody	appeared	to	immunoprecipitate	FUS.		
Figure	11:	Testing	of	FUS	antibodies	in	immunoprecipitation.	A.	Antibody-bound	beads	were	incubated	with	the	nuclear	fractions	from	wild	type	mouse	brains	in	a	hypertonic	buffer.	Following	washes,	protein	was	eluted	in	2x	Laemmli	and	run	on	a	10%	SDS-PAGE,	transferred	to	nitrocellulose	and	developed	using	mouse	monoclonal	FUS-specific	antibody	4H11	from	Santa	Cruz.		
B.	The	cytosolic	fraction	of	wild	type	mouse	brains	was	applied	to	A300-294	bound	beads,	run	on	SDS-PAGE	and	then	western	blotted	for	FUS.			
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		While	FUS	was	specifically	immunoprecipitated	with	the	A300-294	antibody,	but	not	the	control	rabbit	IgG,	a	known	cytosolic	interaction	partner	of	FUS,	Aly/Ref	(Kanai,	Dohmae,	and	Hirokawa	2004),	only	showed	a	weak	signal	in	both	the	IgG	and	 the	A300-294	 IP	samples	 (Figure	13).	 	FUS	was	previously	shown	to	be	 in	complex	with	 kinesins	 and	Aly/Ref,	 so	 perhaps	 this	 interaction	would	 be	 seen	with	 greater	 intensity	 if	 the	 granules	 were	 more	 enriched	 for	 motor	 protein	interactions	 (Kanai,	 Dohmae,	 and	 Hirokawa	 2004).	 Our	 results	 could	 indicate	that	 either	 only	 a	 small	 portion	 of	 FUS	 is	 binding	 Aly/REF	 in	 the	 cytosol	 or	perhaps	the	interaction	itself	is	not	stable	under	our	experimental	conditions.									
FUS	
FUS	
Figure	12:	Immunoprecipitation	of	FUS	by	an	N-terminal	Proteintech	
antibody	(11570-1-AP).	Although	there	appears	to	be	background	binding	of	FUS	to	rabbit	IgG,	the	antibody	immunoprecipitates	FUS	as	shown	in	the	Bio-Rad	Stain-Free	gel	(A)	and	by	immunoblotting	with	Bethyl	A300-302	(B).	
A.	
B.	
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	As	the	antibody	that	worked	best	in	IP,	Bethyl	A300-294,	is	directed	against	the	C-terminal	 PY-NLS	 of	 FUS	 (aa.	 500	 -526),	 which	 is	 largely	 truncated	 in	 the	FusΔNLS	mouse	model	that	I	wanted	to	include	in	my	analysis,	I	tried	an	additional	antibody,	 a	 mouse	 monoclonal	 antibody	 from	 Santa	 Cruz	 (4H11),	 which	recognizes	 a	 more	 N-terminal	 epitope	 (Table	 1).	 4H11	 also	 efficiently	immunoprecipitated	 FUS	 out	 of	 the	 cytosolic	 fraction,	 as	 well	 as	 some	 of	 its	known	 interaction	 partners,	 Aly/REF	 and	 PABP1	 (Figure	 14,	 (Kanai,	 Dohmae,	and	Hirokawa	2004)).	 Some	FUS	did	 remain	bound	 to	 the	 beads	 following	 the	glycine	elution.					
Figure	13:		FUS	from	cytosolic	mouse	brain	fractions	was	
immunoprecipitated	with	the	A300-294	antibody	and	eluted	with	glycine	
pH	2.2.	Prior	to	the	IP,	BSA	and	tRNA	were	added	to	the	beads	to	prevent	nonspecific	binding	of	protein	and	RNA	to	the	beads.	Aly/REF,	a	known	FUS	cytosolic	interaction	partner,	showed	no	or	only	a	very	weak	signal	in	both	the	FUS	and	control-IP.	
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1.3.2.	Optimizing	elution	from	beads		Low	 pH	 glycine	 elution	 from	 beads	 is	 a	 gentle	 way	 to	 remove	 bound	 protein	while	minimizing	antibody	contamination.	In	order	to	fine	tune	a	low	pH	glycine	elution	(pH	3,	0.2M	glycine)	I	then	returned	to	the	nuclear	fraction.	As	the	glycine	appeared	to	cause	the	DNA	in	the	nuclear	fraction	to	precipitate	(assessed	by	the	presence	 of	 a	 white	 precipitate),	 I	 tested	 the	 IP	 with	 and	 without	 DNAse	 I	treatment	 (performed	 prior	 to	 IP).	 Additionally,	 to	 have	 a	 negative	 control	 for	the	 FUS	 antibody,	 I	 also	 incubated	 the	 nuclear	 fraction	with	 rabbit	 IgG-bound	beads.	Two	sequential	glycine	elutions	were	performed,	 followed	by	an	elution	with	2x	Laemmli	buffer	to	see	how	much	FUS	remained	on	the	beads	(Figure	15).			
Figure	14:	Immunoprecipitation	of	FUS	complexes	with	Bethyl	and	Santa	
Cruz	antibodies.	FUS	from	cytosolic	mouse	brain	fractions	(Input)	was	immunoprecipitated	with	either	the	rabbit	Bethyl	antibody	A300-294	or	the	mouse	monoclonal	4H11	antibody	(IP).	Samples	were	then	blotted	for	FUS	(4H11	antibody)	and	potential	complex	partners,	Aly/Ref	and	PABP1.	The	nuclear	fraction	was	loaded	as	a	positive	control	(right	lane).	Both	antibodies	immunoprecipitated	FUS	and	its	interaction	partners	equally	well.		
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	There	 did	 not	 appear	 to	 be	 a	 major	 difference	 between	 DNAse-treated	 and	untreated	samples,	and	FUS	only	was	 immunoprecipitated	by	the	Bethyl	A300-294	antibody,	but	not	the	rabbit	IgG	negative	control.	Although,	it	did	appear	that	the	 glycine	 elution	 was	 not	 entirely	 efficient,	 as	 some	 FUS	 remained	 on	 the	beads,	 therefore	 for	 the	 following	IP,	 I	 lowered	the	pH	of	 the	glycine	to	pH	2.2.	Additionally,	to	prevent	any	nonspecific	binding	to	the	beads,	I	added	a	blocking	step	for	the	beads,	which	included	0.125	mg/ml	yeast	tRNA	and	1	mg/ml	BSA.				Additionally,	 as	 we	 also	 wanted	 to	 examine	 RNAs	 in	 the	 FUS-IPs	 by	 RNA	sequencing	(Figure	5),	I	tested	the	elution	efficiency	of	Trizol	(Figure	16).	I	found	that	Trizol	eluted	as	efficiently	as	Laemmli	buffer.	Low	FUS	signal	in	the	input	is	likely	due	to	limited	antibody	sensitivity.		
Figure	15:	Immunoprecipation	of	FUS	with	Bethyl	A300-294.	Nuclear	fractions	immunoprecipitated	with	the	A300-294	were	eluted	with	sequential	glycine	pH	3	elutions.	Finally,	beads	were	boiled	in	Laemmli	to	examine	how	much	FUS	remained	after	the	glycine	elution.	DNAse	I	was	added	to	the	nuclear	fraction	in	order	to	test	the	effect	of	the	presence	of	DNA	on	the	elution.	A	rabbit	IgG	control	antibody	was	used	as	a	negative	control.		
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		At	this	point,	I	wanted	to	confirm	that	FUS	RNP	complexes	were	still	intact	in	the	cytosolic	fraction	and	additionally,	attempt	to	enrich	for	these	FUS	RNP	granules.			
1.4.	Testing	Different	Methods	to	Enrich	FUS	RNP	Granules		After	successful	nuclear/cytosolic	fractionation	and	immunoprecipitation,	I	next	wanted	to	test	whether	 I	could	 further	enrich	 for	FUS	RNP	granules	by	density	gradient	centrifugation	or	stepwise	centrifugation.		
1.4.1.	Density	gradient	centrifugation		Density	 centrifugation	 provides	 us	 with	 the	 opportunity	 separate	 protein	complexes	 to	 enrich	 RNP	 granules.	 Fortunately,	 the	 Kiebler	 lab	 in	 our	department	 had	 previously	 established	 an	 Optiprep	 protocol	 to	 specifically	isolate	Stau2	and	Btz-containing	mRNP	granules	from	rat	brains.	Briefly,	soluble	lysate	was	generated	from	rat	brain	followed	by	application	of	these	lysates	to	a	15-30%	Optiprep	gradient.	The	gradient	allows	for	separation	of	mRNP	granules	
Figure	16:	Successful	elution	of	the	FUS	complexes	with	Trizol	and	Laemmli.	
A.	A	Bio-Rad	Stain	Free	gel	and	B.	western	blot	of	FUS	using	Bethyl	A300-302.		
FUS	
FUS	
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from	the	main	protein	peak	and	from	the	endoplasmic	reticulum.	Furthermore,	co-segregation	 of	 the	 Stau2	 and	 Btz-containing	 granules	 with	 PABP1	 and	treatment	 of	 the	 soluble	 lysate	 prior	 to	 density	 gradient	 centrifugation	 with	RNAse,	leading	to	a	shift	of	the	Stau2	and	Btz	to	lighter	fractions,	confirmed	the	presence	of	intact	RNP	particles	(Fritzsche	et	al.	2013).			In	short,	I	treated	half	of	the	cytosolic	fraction	with	an	RNAse	I	mixture,	during	this	time	a	15-30%	Optiprep	density	gradient	was	prepared.	The	samples	were	gently	 pipetted	 on	 top	 of	 the	 gradient	 and	 then	 centrifuged	 at	 197,500	 x	 g,	following	centrifugation,	12	fractions	were	collected	beginning	with	the	lightest	fraction	 (Figure	 17).	 Afterwards,	 I	 performed	 a	 chloroform/methanol	precipitation	 to	precipitate	 the	proteins	present	 in	 the	 individual	 fractions	and	analyzed	 them	 by	Western	 blotting	with	 a	 FUS-specific	 antibody,	 PABPC1	was	used	as	a	control	to	confirm	that	granules	were	intact.										
	Interestingly,	 I	 found	FUS	present	 in	all	 fractions	but	primarily	concentrated	 in	the	 lower	 to	 middle	 density	 fractions,	 indicating	 that	 FUS	 is	 both	 diffuse	 and	present	in	various-sized	higher	order	complexes	(Figure	18).	RNAse	I	treatment	resulted	in	a	shift	of	FUS	and	PABPC1	to	lower	density	fractions,	suggesting	that	FUS	is	present	in	intact	mRNP	granules.			
Figure	17:	The	basic	workflow	of	an	optiprep	density	gradient.	Cytosolic	fraction	of	cortex	was	prepared	as	previously	described	and	applied	to	a	15-30%	Optiprep	density	gradient.	High-speed	centrifugation	at	197,500	x	g	was	performed	and	12	fractions	were	collected.	RNP	granules	are	expected	to	be	found	in	fractions	4-6.	
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	Overall,	 it	 can	be	 concluded	 that	FUS	exists	 in	 complexes	of	different	densities	and	no	 enrichment	 is	 seen	 in	 a	 particular	 fraction.	Hence,	 this	method	did	not	seem	 to	 be	 suitable	 to	 further	 enrich	 for	 FUS	 RNP	 granules	 before	immunoprecipitation.			
1.4.2.	Differential	centrifugation	at	20,000	x	g	/	100,000	x	g		
Figure	18:	Optiprep	density	centrifugation	of	cytosolic	mouse	brain.		Fractions	collected	following	Optiprep	centrifugation	were	loaded	onto	a	10%	SDS-PAGE	gel	and	A.	stained	with	Coomassie	or	B.	transferred	to	nitrocellulose	and	blotted	for	FUS	and	PABPC1.	C.	FUS	and	PABPC1	levels	were	quantified	using	ImageJ.	
A.	
B.	
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Next,	 I	 tried	 an	 alternative	 centrifugation	 method	 (two	 separate	 high-speed	centrifugations	 at	 20,000	 x	 g	 and	 then	 100,000	 x	 g)	 in	 order	 to	 test	 in	which	fraction	 FUS	was	 enriched	 and	whether	 the	 complexes	 are	 sensitive	 to	 RNAse	(Figure	19).	This	demonstrated	that	most	FUS	pelleted	at	100,000	x	g,	indicating	that	 it	 may	 associate	 with	 cellular	 membranes	 or	 ribosomes	 (Mallardo	 et	 al.	2003).	Only	very	little	FUS	was	present	in	the	S100	fraction,	making	it	impossible	to	 further	 purify	 FUS	 RNPs	 from	 the	 S100	 fraction.	 Therefore,	 I	 decided	 to	proceed	by	not	using	any	pre-enrichment	steps,	but	by	using	the	entire	cytosolic	fraction	and	immunoprecipiating	FUS	complexes.		
		
	
2.	 Test-IP	 followed	 by	mass	 spectrometry	 and	 RNA-sequencing	 and	
further	optimization	of	the	workflow		Thus	far,	following	cytosolic	fraction,	I	have	been	able	to	successfully	IP	FUS	and	some	of	its	known	interaction	partners.	The	next	step	is	to	do	a	test	run	for	the	mass	 spectrometry.	 First,	 I	 wanted	 to	 confirm	 that	 more	 expected	 interaction	partners	 immunoprecipitated	with	FUS.	 I	 also	wanted	 to	know	 if	different	FUS	antibodies	 yielded	 different	 interactions	 partners	 (perhaps	 due	 to	 epitope	
Figure	19:		Differential	centrifugation	of	cytosolic	mouse	brain.		Cytosolic	fractions	were	incubated	with	RNAse	I	for	1h	at	37°C,	samples	were	then	centrifuged	at	20,000	x	g	and	subsequently	100,000	x	g.	Supernatant	and	pellet	from	each	centrifugation	were	loaded	onto	a	10%	SDS-PAGE,	transferred	to	nitrocellulose	and	subsequently	blotted	for	FUS.		All	of	the	pellet	fractions,	10%	of	the	S20	fractions	and	50%	of	the	S100	fractions	were	loaded.	Densitometry	measurements	were	performed	in	ImageJ,	then	the	ratio	of	the	soluble	to	pellet	fraction	was	calculated	for	each.		
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availability)	 and	 finally,	 I	 needed	 to	 confirm	 that	 I	 had	 enough	material	 in	my	sample	to	detect	interaction	partners.		Therefore,	 I	 decided	 to	 compare	 the	 FUS	 interaction	 partners	 that	 were	 co-immunoprecipitated	 with	 three	 different	 FUS	 antibodies	 in	 parallel	 by	 mass	spectrometry.	 As	 A300-294	 yielded	 promising	 results,	 I	 included	 it	 in	 this	submission	to	examine	the	overlap	between	the	antibodies.	I	also	used	the	Santa	Cruz	 4H11	 mouse	 monoclonal	 antibody,	 which	 recognizes	 an	 epitope	 slightly	more	 N-terminal	 than	 the	 A300-294	 and	 an	 antibody	 recognizing	 the	 N-terminus,	Proteintech	11570-1-AP.	In	order	to	allow	for	better	detection	of	FUS	interaction	partners	and	a	greater	depth	in	the	mass	spec	analysis,	by	reducing	antibody	contamination	in	the	samples,	I	covalently	conjugated	the	antibodies	to	sepharose	 beads	 using	 dimethyl	 pimelimidate	 (DMP),	 a	 chemical	 cross-linker.	Covalent	conjugation	of	the	antibody	to	the	beads	also	allowed	me	to	elute	with	Laemmli	buffer	and	increase	yield.	I	also	removed	the	BSA	and	glycerol	from	the	protocol,	as	they	are	known	to	interfere	with	the	MS	analysis.			As	 I	 only	 submitted	 one	 sample	 per	 antibody,	 I	 was	 unable	 to	 do	 statistical	analysis	 on	 my	 results	 and	 therefore	 simply	 looked	 at	 the	 most	 enriched	proteins.	 All	 antibodies	 showed	 enriched	 FUS	 in	 the	 FUS-IP	 relative	 to	 IgG	control	(Figure	20A),	the	highest	enrichment	was	seen	with	the	Bethyl	antibody,	followed	 by	 the	 Santa	 Cruz	 antibody	 and	 finally	 the	 Proteintech	 antibody.	 Cell	compartment	 classification	 of	 the	 co-IP’d	 proteins	 yielded	 approximately	 the	same	 results	 for	 all	 samples,	with	a	primarily	 cytosolic	 enrichment,	 along	with	significant	 membrane	 and	 nucleus	 enrichment	 (Figure	 20B).	 I	 found	 that	 the	number	 of	 peptides	 identified	 was	 surprisingly	 high	 across	 all	 antibodies	 and	IgG,	 indicating	 potentially	 high	 background.	 Setting	 the	 log2	 fold	 change	 to	 a	conservative	cutoff	of	1	resulted	in	some	overlap	between	the	antibodies	(Figure	20C).	Additionally,	lowering	the	fold	change	threshold	to	a	log2	fold	change	of	.5	(fold	 change	 1.4)	 for	 both	 Santa	 Cruz	 and	 Bethyl	 yielded	 an	 overlap	 of	 84	proteins.	 	The	Proteintech	antibody	had	the	 lowest	amount	of	enriched	protein	with	a	2	or	more	fold	change	and	did	not	yield	many	RNA	binding	proteins.	Upon	submitting	the	results	to	gene	ontology	(GO)	analysis	across	multiple	platforms,	
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including	 Gorilla,	 Panther	 and	 DAVID,	 the	 Proteintech-IP	 did	 not	 yield	 any	enriched	 GO	 categories.	 Both	 the	 Santa	 Cruz-	 and	 Bethyl-IP	were	 enriched	 for	categories	 related	 to	 transport	 (Figure	 20D).	 Due	 to	 the	 possibility	 of	 altered	epitope	availability	in	different	granules,	the	different	epitopes	between	the	two	antibodies	 could	 explain	 the	 different	 interaction	 partners.	 As	 the	 Bethyl	antibody	does	not	recognize	the	FUSΔNLS	mutant	I	planned	to	use,	I	chose	to	move	forward	with	the	Santa	Cruz	antibody		
		
			
Figure	20:	FUS	IP	MS	Results.	A.	The	relative	enrichment	of	FUS	protein	for	each	tested	antibody	compared	to	IgG.	B.	The	total	number	of	quantified	proteins	and	the	quantification	of	the	annotated	cell	compartment.	C.	The	overlap	of	the	proteins	identified	in	the	different	IPs	with	a	log2	fold	change	cutoff	of	1	(2-fold).	D.	GO	enrichment	for	Santa	Cruz	and	Bethyl	antibodies	using	DAVID.	
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The	 next	 step	 was	 to	 confirm	 that	 the	 Santa	 Cruz	 antibody	 could	 in	 fact	immunoprecipitate	different	RNA	transcripts	relative	to	IgG.	I	performed	the	IP	in	 triplicate,	 eluted	 with	 Trizol	 and	 submitted	 the	 eluted	 RNA	 to	 the	 RNA	Sequencing	 facility	 (LAFUGA,	 Gene	 Center).	 As	 there	 should	 not	 be	much	RNA	present	in	the	IgG	control	samples	and	the	RNASeq	involves	a	large	amplification	of	cDNA,	we	spiked	in	control	DNA	(from	another	species)	to	all	of	the	samples	prior	 to	 amplification	 so	 that	 the	 amount	 of	 transcripts	 could	 be	 properly	normalized	between	the	FUS-IP	and	IgG	control.	Unfortunately,	this	first	analysis	did	 not	 yield	 differential	 transcript	 immunoprecipitation	 between	 IgG	 control	and	FUS	antibody.			The	 high	 peptide	 number	 in	 the	 MS	 analysis	 and	 the	 non-differential	immunoprecipitation	of	RNAs	indicated	a	need	to	increase	the	specificity	of	the	IP.	Up	until	this	point,	although	I	had	been	blocking	the	beads	with	tRNA,	I	had	been	using	sepharose	beads,	which	have	reportedly	high	background	binding.	 I	was	also	performing	 the	 immunoprecipitation	 in	hypotonic	buffer,	 followed	by	washes	in	a	buffer	containing	150	mM	NaCl.	It	seemed	possible	that	performing	the	 IP	 in	 hypotonic	 buffer	 reduces	 the	 specificity	 and	 results	 in	 unspecific	binding	of	proteins	and	RNAs	to	the	beads.	Therefore,	I	made	some	adjustments	to	 the	protocol:	 First,	 I	 performed	an	additional	14,000	x	 g	 centrifugation	 step	after	 isolating	the	cytosolic	 fraction,	 to	get	rid	of	sticky	membranes	and	debris.	Second,	I	added	150	mM	NaCl	to	the	hypotonic	14,000	x	g	supernatant	to	reduce	unspecific	 hydrophobic	 interactions	 in	 the	 IP.	 Finally,	 I	 used	 magnetic	 beads	(Dynabeads)	instead	of	sepharose	beads	(Figure	5).				Using	this	new	protocol,	I	performed	the	IP,	eluted	and	isolated	the	RNA	from	the	FUS	antibody	or	IgG-bound	beads	and	then	performed	qPCR	on	two	established	FUS	mRNA	targets	 (GluA1	 and	Nd1-L)	and	one	negative	control	 (Park7,(Lagier-Tourenne	et	al.	2012)).		I	found	enrichment	of	both	GluA1	and	Nd1-L	in	the	FUS	IP	compared	to	IgG	control,	while	the	negative	control,	Park7	was	not	enriched	in	the	FUS-IP	(Figure	21).	In	order	to	further	examine	enrichment	of	FUS	binding	to	
GluA1	 and	Nd1-L,	 I	 normalized	 the	 expression	 of	 the	 bound	 transcripts	 to	 the	cytosolic	input.	
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	Finally,	 I	 needed	 to	 confirm	 that	 the	 new	 protocol	 works	 well	 with	 protein	elution	and	subsequent	mass	spectrometry.	 I	prepared	 two	 test	 samples,	using	both	 the	 Santa	 Cruz	 antibody	 and	 mouse	 IgG..	 Rather	 than	 excising	 multiple	fractions	 from	the	gel,	one	 large	 fraction	was	submitted	 for	a	quick	analysis	by	MS.	 The	 number	 of	 identified	 proteins	 was	 reduced	 by	 22%	 in	 the	 FUS	 IP	compared	to	the	previous	submission,	FUS	was	enriched	by	a	log2	fold	change	of	6	 (64	 fold	 change)	 and	 cytosolically	 localized	 proteins	 remained	 enriched.	 I	decided	 to	 use	 this	 protocol	 for	 the	 quantitative	 comparison	 of	 the	 FUSΔNLS/+	mice	and	their	wild	type	littermates.		
3.	 FUS	 Immunoprecipitation	 from	 FUSΔNLS/+	 vs	 wild	 type	 mouse	
cortices,	followed	by	Western	blot,	RNAseq	and	MS	analysis		
3.1	Western	blot	analysis			As	 the	FUSΔNLS/+	mice	were	not	yet	available	 in	our	animal	 facility	at	 the	time,	 I	obtained	 frozen	 cortices	 isolated	 from	 approximately	 50	 day	 old	 mice	 	 (5	FUSΔNLS/+	mice	and	5	wild	type	littermates,	Table	2)	from	our	collaborator	Diana	Wiesner	(University	of	Ulm).		
Figure	21:	qPCR	of	RNA	eluted	from	the	FUS	immunoprecipitation	(using	the	
4H11	antibody)	confirmed	differential	IP	of	FUS-specific	targets.	RNA	eluted	from	the	beads	underwent	reverse	transcription	followed	by	amplification	for	two	confirmed	FUS	targets,	GluA1	and	Nd1-L	and	a	confirmed	negative	control,	Park.	RNA	bound	to	beads	was	normalized	to	RNA	in	the	input.		
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	The	 cortices	were	 fractionated	 and	 FUS	was	 immunoprecipitated	 according	 to	the	 previously	 established	 procedure	 (Figure	 5).	 To	 verify	 successful	fractionation	and	immunoprecipitation,	I	took	a	small	aliquot	of	the	nuclear	and	cytosolic	fractions	as	well	as	the	IP	fraction	and	analyzed	them	by	Western	blot	with	antibodies	specific	to	FUS,	GAPDH	(as	cytosolic	marker)	and	histone	H3	(as	nuclear	 marker)	 (Figure	 22).	 As	 expected,	 increased	 amounts	 of	 FUS	 were	observed	 in	 the	 cytosolic	 fraction	 in	 the	 FUSΔNLS/+	 cortices	 whereas	 similar	amounts	 of	 FUS	 were	 pulled	 down	 in	 the	 FUS-IP	 between	 the	 two	 genotypes	(Figure	22,	upper	blot).	 	Nuclear/cytosolic	markers	showed	enrichment	in	their	respective	fractions.									
Table	2:	Mice	used	for	the	FUS	interactome	studies.	5	male	wild	type	and	5	male	heterozygous	mice	were	used	for	the	main	experiment.	The	remaining	mice	were	used	for	confirmatory	experiments.	
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3.2.	RNA	sequencing	 to	 identify	differential	RNAs	 in	FUSΔNLS/+	vs	wild	 type	
FUS	RNPs		Single	end	HiSeq	was	performed	using	100	base	pair	reads	on	both	the	cytosolic	input	and	the	FUS	IP.	The	pipeline	can	be	seen	in	Figure	23.			
	
	Unfortunately,	one	sample	from	each	genotype	yielded	poor	quality	and	low	read	count	 in	 the	RNASeq	analysis,	 therefore	we	eliminated	 these	 samples	 from	 the	analysis	and	performed	the	analysis	with	4	wild-type	and	4	FUSΔNLS/+	samples.	In	the	 input	 (cytosolic	 fraction	 before	 IP),	 the	 levels	 of	 only	 two	RNA	 transcripts	significantly	changed	in	mutant	relative	to	wild	type:	Fus,	with	a	log2	fold	change	
Figure	22:	Western	blot	of	the	subcellular	fractionation	and	subsequent	
cytosolic	IP	from	wild	type	and	FUSΔNLS/+	mouse	cortices.	2	mice	are	shown	as	example.		Western	blotting	with	a	FUS-specific	antibody	(4H11,	Santa	Cruz)	demonstrated	increased	cytosolic	localization	of	FUSΔNLS/+	and	equal	immunoprecipitation	efficiency.	Histone	H3	and	GAPDH	antibodies	were	used	to	confirm	successful	preparation	of	a	nuclear	and	cytosolic	fraction		
Figure	23:	RNA	Sequencing	Pipeline.	Following	elution	of	the	RNA	from	the	magnetic	beads	with	Trizol,	RNA	was	purified	with	Zymo’s	Directzol	RNA	Miniprep	Kit,	reverse	transcribed,	multiplexed	and	amplified.	They	were	then	run	through	HiSeq	using	single	end	100	base	pair	reads.	These	reads	were	then	aligned	to	the	genome	using	STAR,	reads	to	each	gene	were	quantified	using	Rsem,	the	IP	was	normalized	to	the	input	(cytosolic	fraction	before	IP)	and	then	differential	RNA	levels	between	FUSΔNLS/+	and	wild	type	was	calculated.	
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(log2FC)	 of	 0.83	 (i.e.	 ~	 1.8-fold	 higher	 in	 mutant	 vs.	 wild	 type)	 and	 Prkch,	 a	protein	kinase	C	family	member,	with	a	log2FC	of	-1.53	(~	3-fold	lower	in	mutant	vs.	wild	type).	The	reads	obtained	from	the	IP	were	then	normalized	to	the	input	to	 account	 for	 slight	 changes	 in	 overall	 mRNA	 levels	 in	 the	 input	 sample	 We	obtained	307	 significant	 changes	with	an	adjusted	p-value	of	0.05	or	 lower.	Of	these	307	changes,	240	were	decreased	 in	mutant	relative	 to	wild	 type	and	67	were	 increased,	 indicating	 that	 there	may	be	 a	 combination	of	 loss-of-function	and	 gain-of-function	 changes	 in	 cytoplasmic	 mRNA	 processing	 in	 FUSΔNLS/+	mutant	mice.	Transcripts	with	a	fold	change	of	more	than	two,	and	a	p-value	of	less	than	0.01	are	shown	in	Figure	24.																				
When	all	of	the	significantly	changed	transcripts	(p<	0.05)	are	subjected	to	gene	ontology	 (GO)	 analysis	 by	 DAVID,	 enrichment	 is	 found	 in	 several	 categories	(Figure	 25),	 of	 which	 the	 top	 enriched	 terms	 are:	 transcription,	 RNA	 binding,	lipid	metabolism,	proteasome,	G-protein	signaling	and	ion	transport.		
Figure	24:	A	heatplot	of	top	differentially	expressed	transcripts.	A	heat	plot	of	individual	transcripts	and	biological	replicates	(4	/	genotype)	with	a	p-value	of	less	than	.01	and	a	fold	change	of	more	than	2	are	shown.	
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3.2.1	 FUSΔNLS/+	 RNP	 granules	 contain	 reduced	 Ric3	 and	 Chrnb2	 mRNAs,	
involved	in	nicotine	receptor	signaling				Our	collaborator	Luc	Dupuis	(Strasbourg)	has	recently	shown	that	the	FUSΔNLS/+	mice	 appear	 to	 have	 aberrant	 nicotine	 signaling	 (personal	 communication,	unpublished).	 	 Therefore,	 I	 parsed	 through	 our	 RNAseq	 results	 for	 transcripts	that	are	related	to	nicotine	receptor	signaling	by	submitting	the	results	to	DAVID	and	 String.	 Two	 candidates	 of	 interest	 include	 Ric3	 and	 Chrnb2.	 Ric3	 mRNA	showed	a	decrease	binding	to	FUS	in	the	heterozygous	mice	of	a	log2	fold	change	of	 -1.12,	 i.e.	 a	 reduction	 of	 >	 2-fold.	 The	 Ric3	 mRNA	 encodes	 a	 protein	 that	promotes	 expression	 of	 nicotinic	 receptors.	 Chrnb2,	 which	 showed	 a	 log2	 fold	change	 of	 	 -0.56	 (i.e.	 a	 reduction	 to	 0.67)	 in	 FUSΔNLS/+	 /wild	 type,	 encodes	 a	nicotinic	acetylcholine	receptor.		This	indicates	that	aberrant	processing	of	Ric3	and	 Chrn2b	 mRNAs	 may	 be	 involved	 in	 the	 phenotype	 and	 aberrant	 nicotine	signaling	observed	in	FUSΔNLS/+	mice.	
Figure	25:	GO	analysis	of	all	significant	transcript	changes	in	the	FUSΔNLS/+	
relative	to	wild	type	mice,	with	highest	enrichment	in	transcription.	Transcripts	in	bold	are	those	I	was	interested	in	following	up.			
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3.2.2.	Alternative	splicing	in	FUSΔNLS/+	mouse	cortex	
3.2.2.1	Alternatively	spliced	transcripts	in	the	cytosolic	fraction		I	 also	 analyzed	 whether	 the	 cytosolic	 fraction	 of	 FUSΔNLS/+	 cortices	 contains	significant	 changes	 in	 alternatively	 spliced	 transcripts	 compared	 to	 wild-type	cortices.			Our	analysis	 in	the	program	Rmats	revealed	357	significant	changes	 in	splicing	events	between	the	FUSΔNLS/+	and	wild	type	cortices.	Most	of	these	changes	were	alterations	 in	 exon	 inclusion	 (Figure	26).	Of	 the	237	 skipped	 exon	 events,	 132	(56%)	 led	 to	 increased	 exon	 inclusion	 in	 FUSΔNLS/+	mice	 while	 the	 remaining	events	led	to	decreased	exon	inclusion	in	FUSΔNLS/+	mice.	The	next	most	enriched	categories	were	equally	alternative	3	and	5’	splice	site	usage,	mutually	exclusive	exon,	followed	by	retained	intron.		
	For	 all	 splicing	 changes	 I	 used	 DAVID	 to	 perform	 GO	 and	 KEGG	 analysis	(annotated	 pathway	 enrichment),	 and	 found	 significant	 enrichment	 in	 the	categories	 poly(A)	 binding,	 transcription,	 proteasome,	 anterograde	 synaptic	vesicle	 transport,	 lipid	 metabolism	 and	 dephosphorylation	 (Figure	 27A).	Interestingly,	there	was	also	enrichment	in	the	RNA	Degradation	KEGG	pathway	(Figure	27B).		
Figure	26:	Alternative	Splicing	analysis	of	transcripts	in	the	cytosolic	fraction	
of	FUSΔNLS/+	vs.	wild-type	mice.	The	primary	alternative	splicing	event	that	is	affected	in	the	FUSΔNLS/+	mice	is	skipped	exons,	followed	by	alternative	3’	and	5’	splice	site	usage,	mutually	exclusion	exon	and	finally	retained	intron.		
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Figure	27:	GO	and	KEGG	Analysis	of	alternatively	spliced	transcripts	in	the	
cytosolic	fraction.	A.	GO	analysis	showed	a	strong	enrichment	in	RNAs	encoding	for	proteins	involved	in	poly	(A)	RNA	binding,	transcription,	proteasome,	anterograde	transport,	lipid	metabolism	and	dephosphorylation.	B.	RNA	Degradation	KEGG	Pathway	showed	enrichment	in	alternatively	spliced	transcripts.				
A.	
B.	
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Looking	 through	 candidates	 with	 the	 largest	 splicing	 changes,	 I	 found	 a	 few	transcripts	 of	 particular	 interest.	 Ddhd1,	 the	 gene	 that	 encodes	 for	phospholipase	A1	has	increased	inclusion	of	exon	3	in	the	FUSΔNLS/+	mice	(Figure	28A).	 Mutations	 in	 this	 gene	 have	 been	 associated	 with	 juvenile	 ALS	 and	hereditary	 spastic	 paraplegia	 (C.	Wu	 and	Fan	2016;	 Liguori	 et	 al.	 2014).	 Ptprf,	encoding	 for	 LAR	 tyrosine	 phosphatase,	 has	 increased	 inclusion	 of	 an	 exon	included	in	an	isoform	other	than	the	canonical	one	which	is	part	of	a	fibronectin	type	III	domain	(Figure	20B).	Alterations	in	the	fibronection	domains	may	affect	extracellular	 binding	 partners.	 As	 LAR	 has	 been	 implicated	 in	 axon	 guidance,	maintenance	 of	 excitatory	 synapses	 and	 cholinergic	 neuron	 size	 and	 number	(Van	 Lieshout	 et	 al.	 2001)	 perhaps	 this	 alternatively	 spliced	 isoform	 might	contribute	to	defects	in	these	areas	in	FUSΔNLS/+		mice.							
			
	
3.2.2.2	Alternatively	Spliced	transcripts	in	the	FUS	IPs		Alternative	splicing	analysis	of	transcripts	identified	in	the	FUS-IPs	yielded	even	more	differences	between	the	cortices	of	FUSΔNLS/+	mice	and	wild	type.	In	total,	I	found	471	changes	between	the	two	genotypes.	As	in	the	cytosolic	fraction,	most	
Figure	28:	Box	plots	of	showing	exon	inclusion	differences	between	FUS	wild	
type	and	mutant,	PSI:	percent	spliced	in.	A.	Ddhd1	shows	increased	inclusion	of	exon	3	in	the	mutant.	B.	Ptprf	has	increased	exon	inclusion	of	exon	13	in	the	mutant.		
A.	 B.	
0.0
0.5
1.0
1.5
Ddhd1
WT dNLS
PS
I
DDhd1
0.0
0.5
1.0
1.5
Ptprf
WT dNLS
PS
I
Legend
	 55	
changes	(68.8%)	were	skipped	exon	events,	followed	by	alternative	3’	splice	site,	mutually	 exclusion	 exon,	 retained	 intron	 and	 finally	 alternative	 5’	 splice	 site	(Figure	29).	This	 indicates	 that	many	alternatively	spliced	transcripts	associate	with	mutant	FUS	in	the	cytoplasm	of	FUSΔNLS/+	mutant	cortices	and	hence	could	be	misregulated	in	the	mutant	mice.		
	GO	analysis	by	DAVID	revealed	extremely	enriched	categories,	with	the	highest	term,	 synapse,	 reaching	 an	 enrichment	 score	 of	 10.9.	 The	 top	 enriched	 GO	categories	 were	 synapse,	 microtubule	 binding,	 transport,	 phosphorylation,	guanyl-nucleotide	exchange	activity	and	poly	(A)	RNA	binding	(Figure	30A).	This	high	 level	 of	 enrichment	 implies	 that	 mutation	 or	 relocalization	 of	 FUS	 has	 a	large	 effect	 on	 the	 specified	 categories.	 KEGG	 pathways	 of	 interest	 include	calcium	signaling	and	long-term	potentiation	(LTP,	Figure	30B	and	C).	
Figure	29:	Summary	of	Alternatively	Spliced	Transcripts	and	FUS	Motif	
Analysis.	Alternative	splicing	analysis	of	the	transcripts	in	the	FUS-IPs	of	FUSΔNLS/+	versus.	wild-type	mice.	The	primary	event	change	in	mice	is	skipped	exon,	then	alternative	3’	usage,	mutually	exclusive	exon,	retained	intron	and	finally	alternative	5’	splice	site	usage.				
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A.	
A.	
B.	
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	Some	highly	altered	candidates	 relevant	 to	nicotinic	 signaling	also	appeared	 in	the	 IP	 data.	 Nrxn1,	 a	 cell	 surface	 receptor	 that	 is	 required	 for	 efficient	neurotransmission	 and	 synaptic	 interactions	 (Pak	 et	 al.	 2015),	 has	 a	 25%	increase	in	the	inclusion	of	exon	7	of	the	canonical	transcript	(Figure	31A).	Exon	7	 makes	 up	 part	 of	 the	 second	 laminin	 G	 domain	 which	 is	 responsible	 for	interactions	with	several	partners	such	as,	neuroligins	and	diacylglycerol	(DAG).	Macf1,	a	protein	responsible	for	crosslinking	actin	to	other	cytoskeletal	elements	and	also	a	microtubule	binder,	has	a	35%	increase	of	inclusion	of	an	exon	which	makes	 up	 the	 microtubule-binding	 Gas2-related	 homology	 domain	 (GAR)	domain	 of	 Macf1	 in	 FUSΔNLS/+	 (Figure	 31B).	 This	 change	 in	 isoforms	 could	potentially	 affect	 microtubule	 localization	 or	 vesicle	 transport.	 	 Apc,	 whose	protein	 product	 is	 involved	 in	 cell	 polarization,	 attachment	 and	 cholinergic	synapse	 formation	 (Temburni	 2004),	 shows	 that	 the	 mutant	 FUS-IP	 has	decreased	 binding	 to	 an	 isoform	 which	 undergoes	 nonsense	 mediated	 decay	
Figure	30:	GO	and	KEGG	analysis	of	alternatively	spliced	transcripts	bound	to	
FUS.	A.	GO	enrichment	analysis	of	the	significantly	different	alternatively	spliced	RNA’s	in	the	FUS-IPs	(FUSΔNLS/+	vs.	WT).	B.	Enrichment	in	the	Calcium	Signaling	KEGG	Pathway.	C.	Enrichment	in	the	Long	Term	Potentiation	KEGG	Pathway.	Alterations	in	these	pathways	and	processes	may	point	us	in	the	direction	of	the	upstream	causes	of	aberrant	neuronal	signaling	and	function.		
C.	
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(Figure	31C).	Gria3,	encoding	for	an	ionotropic	glutamate	receptor,	shows	a	40%	change	in	inclusion	of	14	(Figure	31C).	This	could	potentially	result	in	a	change	between	 the	 isoforms	 flip	 and	 flop,	 thereby	 altering	 the	 speed	 of	 glutamate	receptor	desensitization	(Sommer	et	al.	1990;	Pei	et	al.	2009).		
	
							
Figure	31:	Alternatively	spliced	isoforms	in	HET	vs.	WT	FUS-RNPs.	Sashimi	plots	showing	A.	increased	exon	7	inclusion	in	Nrxn1	and	B.	increased	exon	89	inclusion	in	Macf1	in	FusΔNLS/+	mice	(purple)	relative	to	wild	type	(teal)	as	demonstrated	by	increased	reads	above	stated	exon.	Box	plots	(whiskers	showing	minimum	and	maximum)	showing	C.	decreased	exon	2	inclusion	in	APC	in	the	mutant	mice	D.	and	decreased	exon14	inclusion	in	Gria3.		
C	 D.	
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3.3.	Changes	in	the	protein	composition	of	FUS-RNPs	in	FUSΔNLS/+	mice		In	parallel	 to	 the	RNA	sequencing	analysis,	 I	also	submitted	samples	 for	Liquid	Chromatography/Mass	Spectrometry	(LC/MS).	Following	elution	from	the	beads	with	Laemmli	buffer,	the	samples	were	run	on	SDS-PAGE	gels,	excised	from	the	gel	in	9	fractions	and	then	submitted	to	LC/MS.	One	sample	from	each	genotype	was	 excluded,	 as	 the	 peptide	 measurement	 was	 not	 ideal.	 	 Cell	 compartment	analysis	 revealed	 that	 primarily	 cytosolic	 and	 membrane	 associated	 proteins	were	 identified,	 followed	by	 some	nuclear	proteins.	 (Figure	32A).	Even	 though	the	 mice	 are	 heterozygous	 for	 mutant	 FUS,	 we	 were	 able	 to	 identify	 several	significantly	changed	proteins	in	mutant	vs.	wild-type	FUS-IPs	(Figure	32B).			
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	GO	 analysis	 revealed	 several	 enriched	 categories	 among	 the	 significantly	changed	proteins,	 including	proteins	 involved	in	synapse,	CRD-mediated	mRNA	Stabilization,	poly(A)	RNA	binding,	RNA	splicing,	proteasome	and	myelin	sheath	(Figure	33A).	KEGG	enrichment	showed	an	enrichment	 in	 lysosome	and	mTOR	pathways.	 The	 proteins	 with	 the	 larger	 fold	 changes,	 either	 up	 or	 down,	 are	proteins	involved	in	RNA	binding,	cytoskeleton	and	proteasome	(Figure	33B).	An	interesting	 result	 is	 that	 four	 proteins	 from	 the	 Septin	 family	 came	 up	 as	significantly	changed,	implying	that	the	interaction	between	FUS	and	the	septin	protein	family	may	be	altered	in	FUSΔNLS/+	mice.	As	seen	in	the	GO	analysis,	there	was	 also	 enrichment	 in	 binding	 of	 proteins	 associated	with	 the	 proteasome	 in	FUSΔNLS/+	mice,	indicating	an	increased	association	with	the	proteasome.		
Figure	32:	Cell	compartment	analysis	and	volcano	plot	of	identified	
peptides.	A.	Characterization	of	annotated	protein	localization	in	the	FUS	IP.	Proteins	annotated	to	be	associated	with	the	cytoplasm	and	membrane	were	of	the	top	identified	groups.	B.	A	volcano	plot	displaying	all	changed	protein,	those	in	red	are	significantly	different	(p<0.05)	between	wild-type	and	FUSΔNLS/+	-IPs.		
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Figure	33:	Analysis	of	protein	interactors	significantly	changed	between	
FUS	wild	type	and	FUSΔNLS/+	IPs.	A.	GO	Enrichment	of	significantly	different	proteins	found	in	the	FUS	IP.	B.	Largest	Log2-fold	changes	between	wild	type	and	mutant	FUS-IPs	(among	significantly	different	interactors,	all	p<0.05)			
A.	
B.	
A.	
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4.	FUSΔNLS/+	target	and	interactome	validation		
4.1.	Attempts	to	Establish	Primary	Neuronal	Cultures	from	FUSΔNLS/+	mice		As	 one	 of	 the	 goals	 of	 the	 project	 was	 to	 functionally	 follow	 up	 interesting	candidates	 from	 the	 RNAseq	 and	 MS	 analysis	 and	 more	 clearly	 elucidate	 the	functional	role	which	FUS	plays	in	the	neuronal	cytoplasm,	I	wanted	to	establish	primary	neuronal	cell	culture	from	FUSΔNLS/+	mice	 in	our	 lab.	 	As	this	technique	had	not	previously	been	set	up	 in	our	 lab,	 I	 first	 started	with	wild	 type	mouse	cultures.		The	mice	were	imported	into	our	facility	in	February	2018	and	due	to	breeding	problems,	it	took	longer	to	expand	the	colony	than	anticipated.	Therefore,	I	was	only	able	to	obtain	one	viable	neuronal	culture.	In	this	culture,	I	stained	for	FUS	with	two	of	our	FUS	antibodies	to	confirm	the	expected	cytosolic	mislocalization	of	FUSΔNLS	in	the	heterozygotic	mice	and	to	visualize	the	various	staining	patterns	each	antibody	gives	(Figure	34).																		
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Figure	34:	Immunostaining	of	FUSΔNLS/+		(Fus	dNLS	+/-)	and	wild	type	mice	
cortical	neurons	with	FUS	antibodies.	Staining	with	4H11	or	Bethyl	antibody	A300-302	yielded	approximately	the	same	staining	pattern	with	slightly	more	cytosolic	granular	staining	with	the	Bethyl	antibody.	
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4.2	 Analyzing	 candidates	 from	 the	 MS	 analysis	 in	 a	 FUS	 WT	 vs.	 FUSΔNLS	
expressing	cell	line		
4.2.1	FUS	and	Septin	Interactions		As	 I	 was	 not	 able	 to	 regularly	 obtain	 neuronal	 cultures	 of	 FUSΔNLS/+	 mice,	 I	decided	 to	perform	some	validation	experiments	 in	HeLa	cells	expressing	FUS-WT	 vs.	 FUSΔNLS,	 in	 order	 to	 follow	up	 on	 some	 of	 the	 observed	 changes	 in	 the	FUS-RNP	 granule	 composition	 in	 FusΔNLS/+	 mice.	 I	 used	 FUS	 knockout	 HeLas	(obtained	 from	 our	 collaborator	Marc-David	 Rüpp)	 and	 transfected	 them	with	either	a	wild	type	FUS	or	a	FUS	514X	HA-tagged	expression	plasmid.	After	either	48	or	72h	of	expression,	I	performed	immunostaining	for	FUS	and	either	Septin-2,	 7,	 Caprin2	 or	 HuD	 to	 check	 whether	 expression	 of	 FUS-514X	 results	 in	 an	altered	localization	of	any	of	the	candidate	proteins	(Figures	35	and	36).	There	was	 no	 difference	 in	 the	 localization	 of	 Sept2,	 Sept7,	 Caprin2	 or	 HuD	 in	 cells	expressing	mislocalized	FUS-R514X.			 	
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Figure	35:	Septin	2	and	7	staining	upon	expression	of	either	FUS	wild	type	or	
514x.	Septin	2	and	7	localization	remain	unchanged	with	mutant	FUS	expression.	
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	Additionally,	I	performed	a	double	transfection	of	FUS	knockout	HeLas	with	FUS	(wt	or	514x)	and	Sept2-GFP	or	Sept7-GFP	(gifts	 from	Helge	Ewers,	Berlin)	and	again	 fixed	at	48	and	72h	post-transfection.	 	This	did	not	 yield	 any	 changes	 in	localization	of	 the	two	septins	 in	mutant	FUS-expressing	cells	 in	comparison	to	FUS-WT	expressing	cells	(Figure	37).				
Figure	36:	HuD	and	Caprin2	staining	upon	expression	of	either	FUS	wild	
type	or	514x.	HuD	(A)	and	Caprin2	(B)	localization	remain	unchanged	with	mutant	FUS	expression.	
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Figure	37:	Septin	2	and	7	localization	following	transfection	with	Sept2	or	7	
and	either	FUS	wild	type	or	514x.	There	was	no	change	in	localization	of	either	Septin	2	or	7	48	hours	following	double	transfection	of	either	Sept2	or	7	in	conjunction	with	either	FUS	wild	type	or	514x.			
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4.2.2.	FUS	514X	and	recruitment	into	stress	granules	following	heat	shock		Upon	heat	shock	or	other	types	of	cellular	stress,	mutant	FUS,	but	not	wild	type,	has	 been	 shown	 to	 relocalize	 into	 stress	 granules	 (Bentmann	 et	 al.	 2012).	Therefore,	 I	 was	 interested	 to	 know	 if	 FUS	 514X	 also	 recruits	 any	 of	 the	candidate	 interactors	 into	 the	 stress	 granules.	 I	 transfected	HeLa	 FUS	KO	 cells	with	either	wild	type	FUS	or	FUS	R514X,	and	after	48	hours,	I	heat	shocked	the	cells	 for	 1h	 at	 44°C	 then	 stained	 for	 Septin	 7	 and	 2,	 HuD,	 and	 HNRNPUL1.	Although	 FUS-R514X	 was	 nicely	 recruited	 into	 heat	 shock-induced	 stress	granules,	as	visualized	by	co-staining	for	the	SG	marker	protein	TIA-1,	there	was	no	co-recruitment	of	any	of	 the	candidate	proteins	along	with	mutant	FUS	 into	SGs	(Figures	38	and	39).			 				
A.		
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Figure	38:	FUS	wild	type	or	514x	colocalization	with	Septins	following	
heatshock.	FUS	KO	HeLas	were	transfected	with	either	FUS	wt	or	514x,	after	48h	they	underwent	heat	shock	and	were	immediately	fixed	and	stained	for	FUS	and	
A.	Septin	2	(control)	B.	Septin	2	(heat	shock)	C.	Septin	7	(control)	D.	Septin	7	(heat	shock).		
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Figure	39:	FUS	wild	type	or	514x	colocalization	with	HuD	and	hnRNPuL1	
following	heatshock.	FUS	KO	HeLas	were	transfected	with	either	FUS	wt	or	514x,	after	48h	they	underwent	heat	shock	and	were	immediately	fixed	and	stained	for	FUS	and	A.	hnRNPUL1	(control)	B.	hnRNPUL1	(heat	shock)	C.	HuD	(control)	D.	HuD	(heat	shock)		
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4.2.3.	Investigation	into	the	interaction	between	FUS	and	the	Proteasome		As	 several	 proteasomal	 subunits	 showed	 increased	 levels	 in	 the	 FUS-IPs	 from	FUSΔNLS/+	mice	 (Figure	33),	 I	wanted	 to	 test	whether	 there	may	be	 a	 change	 in	proteasome	 activity	 in	 FUSΔNLS/+	 expressing	 cells,	 e.g.	 by	 sequestration	 of	 the	proteasome	 or	 proteasomal	 subunits	 by	mutant	 FUS.	 	 In	 order	 to	 address	 this	question,	 I	 obtained	 a	 proteasomal	 activity	 reporter,	 UbG647V-GFP,	 from	 the	Marc	Hipp,	MPI	Biochemistry,	Munich.		Upon	disruption	of	the	proteasome,	this	ubiquitin	 reporter	 accumulates	 in	 the	 cell	 and	 yields	 higher	 GFP	 levels.	 To	measure	 proteasome	 activity,	 I	 transfected	 the	 FUS	 KO	 HeLa	 cells	 with	 either	FUS	WT	or	R514X	along	with	the	proteasome	reporter.	 	As	a	positive	control,	 I	treated	cells	with	MG132,	a	known	proteasome	 inhibitor.	After	48h,	 I	 fixed	 the	cells,	and	stained	for	FUS	and	analyzed	the	cells	by	confocal	microcopy	(Figure	40).	 While	 treatment	 with	 MG132	 showed	 a	 dramatic	 increase	 in	 reporter	accumulation,	 no	 GFP	 signal	 accumulated	 in	 FUS	WT	 or	 FUSR514X-expressing	cells.	 	As	this	experiment	was	carried	out	by	transient	transfection	of	both	FUS	and	the	reporter,	it	is	possible	that	the	timeframe	was	not	long	enough	observe	meaningful	changes.													 	
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Figure	40:	Proteasomal	Activity	Upon	Expression	of	either	FUS	WT	or	
514x.	FUS	KO	HeLa’s	were	transfected	with	a	proteasomal	activity	reporter,	UbG647V-GFP	and	either	FUS	WT	or	FUS	514x.	48h	following	transfection,	cells	were	either	untreated,	treated	with	DMSO	or	treated	with	MG132,	fixed	5	hours	later	and	stained	for	FUS.	
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III.	Discussion		
1.	The	FUS	RNA	and	Protein	Interactome		As	 FUS	 is	 primarily	 present	 in	 the	 nucleus,	 previous	work	 on	 FUS	 has	 largely	focused	 on	 its	 nuclear	 role.	 It	 plays	 an	 important	 role	 in	 transcription	 and	splicing	 (Polymenidou	 et	 al.	 2011;	 Ishigaki	 et	 al.	 2012;	 Lagier-Tourenne	 et	 al.	2012;	Rogelj	et	al.	2012;	Zhou	et	al.	2013).	More	recently	groups	started	to	look	at	 Fus	 outside	 of	 the	 nucleus	 (Belly	 et	 al.	 2005;	 Fujii	 et	 al.	 2005;	 Fujii	 2005;	Udagawa	et	al.	2015)	and	have	discovered	that	FUS	may	be	important	in	mRNA	localization,	stabilization	and	possibly	translation.	Most	FUS	 interaction	studies	have	focused	on	the	entire	cell,	causing	the	dataset	to	be	dominated	by	nuclear	interactors	(Reber	et	al.	2016;	Hoell	et	al.	2011;	Lagier-Tourenne	et	al.	2012;	S.	Sun	 et	 al.	 2015;	 Kamelgarn	 et	 al.	 2016)	 	 	 Thus	 far	 the	 only	 study	 focused	 on	cytosolic	FUS	RNA	targets	was	done	by	Colombrita	and	colleagues	in	2012,	who	isolated	FUS	RNA	 targets	 from	 the	 cytosol	 of	NSC-34,	 a	motor	neuron	 cell	 line	cells	and	only	for	wild	type	FUS	(Colombrita	et	al.	2012).	In	this	study	only	wild	type	FUS	was	studied.	To	date	no	studies	of	cytosolic	protein	interactors	of	FUS	have	 been	 carried	 out	 prior	 to	 the	 work	 described	 in	 this	 thesis.	 In	 order	 to	obtain	 a	 more	 complete	 picture	 of	 the	 FUS	 interactome,	 I	 used	 intact	 mouse	cortex	to	analyze	both	RNA	and	protein	interactors.	I	compared	the	FUS	RNA	and	protein	 interactome	 of	 wild	 type	 to	 an	 ALS	 mouse	 model	 with	 cytosolic	mislocalization	of	FUS	to	reveal	disease-related	changes.		
1.1.	Conclusions	from	RNAseq		
1.1.1.	Changes	in	RNA	Expression	and	Splicing	in	FUSΔNLS/+	mice		I	 found	 very	 few	 changes	 in	 the	 overall	 abundance	 of	 RNAs	 in	 the	 cytosolic	fraction	but	several	differentially	expressed	alternative	splice	isoforms.	The	FUS	IP	 revealed	 a	 large	 number	 of	 changes	 in	 both	 gene	 and	 transcript	 level	abundance	(Figures	25-27).	The	lack	of	gene	level	expression	changes	relative	to	the	 large	 amount	 of	 transcript	 level	 changes	 in	 the	 cytosol	 could	 indicate	 that	FUS	plays	more	of	a	role	 in	alternative	splicing,	 rather	 than	overall	expression.	
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As	splicing	occurs	 in	 the	nucleus,	 this	would	 imply	 that	 the	nuclear	 function	of	FUS	is	affected	in	the	Fus	ΔNLS/+	mouse	line.		Interestingly,	Dupuis	and	colleagues	show	no	change	in	nuclear	FUS	expression	(Scekic-Zahirovic	et	al.	2017).	FUS	has	been	 shown	 to	 interact	via	 its	C-terminus	with	various	SR	proteins	 to	 regulate	splicing	(Yang	et	al.	1998).	As	 the	NLS	 is	missing	 from	these	mice,	perhaps	 the	NLS	is	functionally	important	for	splicing.	Finally,	the	small	amount	of	cytosolic	gene	level	RNA	changes	is	not	particularly	surprising	as	I	analyzed	a	single	time	point,	 at	 a	 very	 early	 stage,	 heterozygous	 mouse	 model.	 Other	 groups	 using	mouse	lines	with	an	altered	FUS	C-terminus	have	performed	total	cell	RNASeq	at	early	 timepoints	 have	 also	 shown	minimal	 expression	 changes	 (Funikov	 et	 al.	2018;	Devoy	et	al.	2017).			
1.1.2.	 Comparison	with	published	RNASeq	data	 from	aged	Fus	 ΔNLS	mouse	
line		The	creators	of	our	mouse	model,	 the	Dupuis	 lab,	performed	RNAseq	on	e18.5	homozygous	 Fus	 ΔNLS/+	 whole	 brains	 (Scekic-Zahirovic	 et	 al.	 2016)	 and	 on	 the	spinal	 cords	 of	 22-month-old	 Fus	 ΔNLS/+	 mice	 (Scekic-Zahirovic	 et	 al.	 2017).	However,	 they	 did	 not	 focus	 on	 the	 cytoplasmic	 fractions	 and	 hence	 did	 not	specifically	 look	 for	changes	 to	cytosolic	RNAs	 levels.	 In	 the	aged	heterozygous	mice,	they	also	did	not	analyze	splicing	changes,	only	RNA	level	changes.			In	 the	 spinal	 cords	 of	 aged	 Fus	 ΔNLS/+	 mice,	 they	 found	 several	 altered	 RNA	transcripts	 related	 to	 myelination,	 most	 of	 them	 downregulated,	 implying	 an	oligodendrocytic	 involvement	 in	 motor	 degeneration.	 While	 I	 did	 not	 find	 GO	enrichment	in	transcripts	related	to	myelination,	this	difference	could	be	due	to	the	 fact	 that	 I	 used	 cortex	 and	 they	 analyzed	 spinal	 cord	 and	 because	 we	examined	different	time	points.			Although	it	is	difficult	to	compare	Fus	ΔNLS/	ΔNLS	e18.5	brains	with	cortices	of	Fus	ΔNLS/+	50	day	old	mice,	as	the	former	is	very	much	in	a	developmental	state,	there	is	 some	 overlap	 between	 the	 alternative	 splicing	 patterns.	 Between	 the	 two	datasets,	10	transcripts	have	significant	differential	splicing,	of	those	10,	5	show	
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changes	 in	alternative	splicing	of	 the	same	exon	(Table	3).	Excluding	Hnrnph2,	the	 splicing	 changes	 are	 in	 the	 same	 direction	 (both	 either	 decreased	 or	increased	 inclusion	 in	 mutant	 mice).	 Two	 interesting	 transcripts	 that	 show	altered	 splicing	 in	 Fus	 ΔNLS/+	 mice	 are	 Kcnq2	 and	 Ntng1.	 Kcnq2	 encodes	 for	 a	potassium	channel	that	plays	an	important	in	role	in	neuronal	excitability.	Ntng1,	Netrin	G1,	is	a	known	splicing	target	of	FUS	(Orozco	and	Edbauer	2013).	Netrins	play	an	 important	 role	 in	development	and	Ntng1	 is	particularly	 important	 for	axon	 guidance,	 synapse	 formation	 and	 maintenance	 (Yin,	 Miner,	 and	 Sanes	2002).	Ntng1	has	several	splice	isoforms	and	its	alternative	splicing	in	response	to	 FUS	 knockdown	 has	 been	 reported	 by	 several	 groups	 (Ishigaki	 et	 al.	 2012;	Rogelj	 et	 al.	 2012;	 Lagier-Tourenne	 et	 al.	 2012;	 Nakaya	 et	 al.	 2013),some	 of	which	report	changes	in	alternative	splicing	of	the	same	exon		(exon	7)	as	we	and	the	Dupuis	group	have	found.	It	has	been	hypothesized	that	alternative	splicing	may	 result	 in	 altered	 ligand	 affinity.	 Perhaps	 the	 expression	 of	 the	 alternative	splice	 isoform	 in	 FUS	mutant	mice	 results	 in	 changes	 to	 synapse	maintenance,	resulting	 in	 altered	 synaptic	 activity	 and	 possibly	 increased	 synaptic	vulnerability.										
		
Table	3:	Overlap	of	alternatively	spliced	transcripts	between	heterozygous	
and	homozygous	Fus	ΔNLS	mice.	Alternatively	spliced	transcripts	that	show	an	altered	splice	isoform	pattern	in	both	Fus	ΔNLS	homozygotic	embryos	(Dupuis)	and	the	Fus	ΔNLS	heterozygotic	adult	cortices	cytosol	(this	study).	In	bold	are	transcripts	with	changes	in	the	same	exon	in	both	datasets.		
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1.1.3.	Involvement	of	FUS	in	the	nicotinic	signaling	pathway		In	 correspondence	 with	 the	 Dupuis	 lab,	 we	 have	 learned	 that	 they	 have	 been	unable	to	culture	primary	neurons	derived	from	Fus	ΔNLS	/	ΔNLS	embryos,	as	these	neurons	die	after	approximately	8	days	in	culture	(Diana	Wiesner,	unpublished	data).	They	found	that	the	survival	of	Fus	ΔNLS	/	ΔNLS	neurons	can	be	rescued	with	nicotine.	 Because	 of	 this	 finding,	 they	 treated	 FUS	 ΔNLS	 /	 +	 mice	 with	 nicotine.	Surprisingly,	the	mice	were	completely	resistant	to	the	effects	of	nicotine	relative	to	wild	type	littermates.	We	therefore	scrutinized	our	RNASeq	data	for	any	clues	that	may	 explain	 defects	 in	 the	 nicotinic	 pathway.	 	We	 found	 that	Chrnb2	 and	
Ric3	mRNA	 levels	were	decreased	 in	 the	cytosolic	FUS-IP	 in	Fus	ΔNLS	/+	mice	vs.	wild-type	mice	(Chrnb2:	 log2	fold	change	=	0.56;	Ric3:	 log2	fold	change	=	1.12).	Chrnb2	 is	 a	 type	 alpha	 4	 beta	 2	 nicotinic	 acetylcholine	 receptor,	 and	 Ric3	functions	as	a	chaperone	to	nicotinic	acetylcholine	receptors	(Rempel	et	al.	1998;	Halevi	et	al.	2002).	In	our	splicing	analysis,	we	found	alternative	splice	isoforms	of	 Apc,	 Macf1,	 Nrxn1	 and	 Ptprf	 in	 Fus	 ΔNLS	 mice	 vs.	 wild-type	 controls.	 The	proteins	 encoded	 by	 these	 mRNAs	 could	 be	 involved	 in	 nicotinic	 receptor	assembly	 and	 interestingly,	 Nrxn1	 is	 a	 known	 splicing	 target	 of	 FUS	 (Lagier-Tourenne	 et	 al.	 2012;	 Nakaya	 et	 al.	 2013).	 Apc	 and	 Macf1	 associate	 with	microtubules	and	are	important	for	axonal	guidance.	Nrxn1	is	vital	for	synaptic	transmission	 and	 certain	 polymorphisms	 have	 been	 related	 to	 nicotine	dependence	 (Nussbaum	 et	 al.	 2008).	 Ptprf,	 also	 known	 as	 LAR,	 has	 been	implicated	 in	 axon	 guidance,	 development	 and	 maintenance	 of	 excitatory	synapses	 and	 is	 important	 for	 cholinergic	neuronal	number,	 size	 and	 targeting	(Dunah	et	al.	2005)	(Van	Lieshout	et	al.	2001).		In	order	to	follow	up	on	some	of	these	interesting	candidates	from	our	RNASeq	analysis,	one	could	study	whether	their	mRNA	and/or	protein	levels	are	changed	at	synapses	of	Fus	ΔNLS	/+	mice.	This	could	be	done	by	performing	synaptosomal	preparations,	 running	 qPCR	 on	 the	 RNAs	 and	 immunoblotting	 against	 the	proteins.	Additionally,	using	primary	neuronal	culture	and	confocal	microscopy,	one	could	look	at	both	RNA	and	protein	localization.			
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1.1.4.	RNAs	that	show	differential	binding	to	cytosolic	Fus	ΔNLS	/+	vs.	FUS-WT			GO	 analysis	 showed	 enrichment	 in	 several	 categories,	 including	 Transcription,	RNA	 Binding,	 Lipid	 Metabolism,	 Proteasome,	 G-protein	 Signaling	 and	 Ion	Transport	 (Figure	 25),	 indicating	 that	 mRNAs/proteins	 from	 these	 functional	categories	may	be	disturbed	 in	Fus	 ΔNLS	/+	mice.	Reduced	binding	 to	 transcripts	encoding	RNA-binding	 proteins	 could	 indicate	 that	 the	 fate	 of	 these	mRNAs	 in	the	 cytoplasm	 is	 altered,	 e.g.	 in	 terms	 of	 mRNA	 stability,	 transport	 or	 local	translation.	This	could	result	in	altered	levels	of	the	encoded	RBPs,	or	in	altered	local	 production	 of	 the	 corresponding	 RBP,	 thereby	 altering	 cytosolic	 RNP	granule	composition	and	dynamics.	For	example,	Nono	mRNA	shows	decreased	binding	to	Fus	in	Fus	ΔNLS	mice	compared	to	wildtype	controls	(log2	fold	change	=	-0.93).	Interestingly,	An	et	al.	recently	found	in	a	SH-SY5Y	of	Fus	ΔNLS	model	that	FUS	 and	 Nono	 have	 reduced	 interaction,	 causing	 dysfunction	 in	 paraspeckle	formation	(An	et	al.	2019).			FUS	 may	 regulate	 translation,	 disruption	 of	 the	 NLS	 in	 mouse	 models	 causes	translation	to	become	misregulated,	whether	the	effect	is	only	on	axonal	protein	synthesis	or	global,	is	still	under	debate	(López-Erauskin	et	al.	2018;	Kamelgarn	et	 al.	 2016).	 It	 is	 therefore	 possible	 the	 binding	 of	 FUS	 to	 different	 transcripts	results	in	either	impeded	or	differential	translation	of	these	transcripts.	Perhaps	we	are	seeing	the	very	early	stages	of	a	disruption	in	translation.			
1.1.5.	Alternative	splicing	changes	in	FusΔNLS/+	mice	cortices		Both	 the	 cytosolic	 input	 and	 the	 immunoprecipitated	 fraction	 contained	many	interesting	 splicing	 changes	 in	 Fus	 ΔNLS/+	mice	 compared	 to	wild-type	 controls,	primarily	splicing	events	 involving	skipped	exons	(Figures	26	and	29).	Splicing	changes	 in	 the	 cytosolic	 fraction	 were	 enriched	 in	 the	 GO	 categories	 RNA	binding,	 Transcription,	 Proteasome,	 Anterograde	 Transport,	 Lipid	 Metabolism	and	Dephosphorylation	(Figure	27).	Interestingly,	there	was	also	an	enrichment	in	 the	KEGG	pathway	RNA	degradation.	Aside	 from	splicing	changes	 in	mRNAs	involved	 in	 to	 the	 nicotinic	 pathway	 (discussed	 above),	 another	 individual	
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candidate	of	interest	is	Ddhd1,	a	gene	that	encodes	for	phospholipase	A1	and	is	responsible	for	hydrolyzing	phosphatidic	acid.	Mutations	in	this	gene	have	been	associated	with	 juvenile	ALS	and	hereditary	spastic	paraplegia,	possibly	due	 to	altered	 lipid	metabolism	 (C.	Wu	 and	 Fan	 2016;	 Liguori	 et	 al.	 2014)	 .	 Different	isoforms	 may	 change	 substrate	 specificity.	 It	 is	 possible	 that	 a	 change	 in	substrate	specificity	of	this	type	could	result	in	altered	energy	metabolism.		Alternatively	spliced	transcripts	in	the	FUS	IP	were	enriched	in	the	GO	categories	Synapse,	 Microtubule	 Binding,	 Transport,	 Phosphorylation,	 GEF	 Activity	 and	Poly	 (A)	 RNA	 Binding	 (Figure	 30)	 as	 well	 as	 the	 KEGG	 pathways	 Calcium	Signaling	 and	 Long	 Term	 Potentiation.	 This	 could	 indicate	 that	 FUS	 in	 the	cytoplasm	is	associated	with	mRNAs	that	are	vital	 for	intracellular	transport	as	well	as,	synaptic	signaling	and	integrity.			Glutamate	 receptors	 are	 critical	 for	 cell	 signaling	 and	 survival.	 FUS	 has	 an	intricate	relationship	with	glutamate	receptors,	stimulation	of	mGluR5	results	in	FUS	 translocation	 to	 spines	 (Fujii	 et	 al.	 2005)	 and	 FUS	 regulates	GluA1	mRNA	stability	 (Udagawa	 et	 al.	 2015).	GluA1	mRNA	was	 identified	 in	 the	 FUS	 IP,	 but	there	 is	no	difference	 in	 the	binding	between	wild	 type	and	mutant.	But	we	do	see	a	difference	in	the	alternative	splicing	of	exon	14	of	Gria3,	another	glutamate	receptor	 subunit.	 Alternative	 splicing	 of	 this	 exon	 would	 result	 in	 a	 change	between	 flip	 and	 flop	 isoforms,	 which	 have	 different	 receptor	 desensitization	rates	 (Pei	 et	 al.	 2009).	 Altered	 presence	 of	 the	 flip	 or	 flop	 isoforms	 in	 other	glutamate	receptors	has	been	shown	 to	 increase	susceptibility	 to	excitotoxicity	and	alter	neuron	excitability	(Y.	H.	Park	et	al.	2016;	Lykens	et	al.	2017).			It	would	 be	 interesting	 to	 follow	 up	whether	 a	 change	 in	 flip/flop	 isoforms	 of	Gria3	 are	 also	 seen	 on	 the	 protein	 level	 and	 whether	 this	 causes	 changes	 of	either	 Gria3	 localization	 or	 expression	 levels.	 If	 this	 would	 be	 confirmed,	 one	could	also	examine	FUSΔNLS/+	neuron	response	to	Gria3	stimulation.			
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1.1.6.	RNASeq	Follow	Up		The	 RNASeq	 results	 give	 us	 specific	 candidates	 that	 show	 altered	 FUS	interaction.	 The	 next	 step	 would	 be	 to	 determine	 what	 this	 means.	 Do	 the	proteins	 produced	 from	 the	 differentially	 binding	 RNAs	 have	 aberrant	localization	 or	 expression	 levels?	 This	 could	 be	 addressed	 by	 performing	immunohistochemistry	 and	 either	 western	 blot	 or	 ELISA	 on	 cortices	 or	synaptosomal	preparations	of	the	FusΔNLS/-	mice	or	by	immunostaining	FusΔNLS/-	primary	 neurons.	 	 If	 the	 proteins	 are	 mislocalized,	 this	 could	 be	 due	 to	mislocalization	 of	 their	 mRNA.	 If	 mutant	 Fus	 is	 causing	 mislocalization	 of	 its	target	 mRNAs,	 performing	 FISH	 on	 either	 cultured	 neuron	 or	 brain	 sections	could	verify	this.		If	the	encoded	proteins	show	altered	levels,	what	is	the	underlying	mechanism?	Is	altered	FUS	binding	causing	changes	 to	mRNA	stability	or	 to	 translation?	Or	perhaps	mutant	FUS	is	altering	proteasomal	activity.	First,	one	must	determine	the	best	 system	 in	which	 to	 follow	up.	My	 study	was	performed	 in	50	day	old	mouse	 cortices,	 while	 continuing	 in	 mice	 would	 provide	 valuable	 insight,	 it	comes	 with	 constraints.	 Aside	 from	 time	 to	 age	 the	 mice	 (repeating	 the	experiments	at	later	time	points	would	be	extremely	valuable)	and	the	difficulty	to	 introduce	 expression	 constructs,	 the	 cortex	 is	 full	 of	 many	 cell	 types.	Therefore,	we	cannot	say	that	the	changes	we	observe	are	from	neurons	and	we	may	 be	 missing	 cell-specific	 changes.	 Performing	 the	 initial	 follow-up	experiments	 in	 vitro	 or	 in	 dissociated	 primary	 neurons	would	 be	 a	 good	 first	step	 to	 further	understand	 the	role	of	FUS	 in	mutant	and	wild	 type	conditions.	While	cultured	neurons	come	from	a	developing	embryo	(resulting	in	a	different	transcriptome	 and	 proteome	 than	 adult	 mice)	 and	 can	 be	 more	 difficult	 to	express	 constructs,	 they	 would	 allow	 us	 to	 look	 in	 a	 neuron,	 compartment-specific	manner	at	RNA	localization	and	translation.	Since	they	are	derived	from	embryos,	we	would	also	be	able	to	compare	homozygous	neurons	and	perhaps	see	more	robust	RNA	regulation	changes.		
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A	 commonly	 used	 method	 to	 address	 mRNA	 stability	 involves	 inhibiting	transcription	with	 Actinomycin	 D	 and	 then	measuring	mRNA	 levels	 over	 time	with	 either	 qPCR	 or	 Northern	 Blot.	 This	 experiment	 could	 be	 tested	 in	 either	primary	neurons	or	HeLa	cells	expressing	either	mutant	or	wild	type	FUS.	In	the	case	that	mutant	FUS	negatively	affects	mRNA	stability,	 the	mRNA	would	more	rapidly	decay	over	time.	The	role	of	FUS	in	mRNA	translation	could	be	addressed	either	 in	 vitro	 or	 in	 a	 cell-based	 assay.	 One	 way	 to	 do	 this	 would	 be	 with	 a	reporter	 assay,	 such	 as	 luciferase.	 It	 could	 be	 performed	 in	 vitro	 with	 rabbit	reticulocyte	 lysate,	 the	 target	 of	 interest	 plus	 luciferase	 and	 FUS.	 As	 FUS	functions	 cooperatively	 and	 perhaps	 in	 a	 location-specific	manner,	 an	 assay	 in	neurons	 may	 be	 better	 suited	 to	 address	 this	 question.	 One	 could	 transfect	 a	reporter	attached	to	the	3’	UTR	of	 the	target	of	 interest,	such	as	 luciferase	or	a	SunTag	(Yan	et	al.	2016),	 into	Fus	ΔNLS/	+expressing	and	wild	type	neurons.	The	readout	 of	 both	 assays	 would	 show	 if	 there	 is	 an	 increase	 or	 decrease	 in	translation	in	the	presence	of	mutant	FUS.				
1.2.	Changes	in	the	cytosolic	FUS	protein	interactome	in	FusΔNLS/+	mice		FusΔNLS/+	 mice	 have	 an	 altered	 cytosolic	 FUS	 protein	 interactome.	 The	mechanism	 by	 which	 this	 arises	 could	 be	 due	 to	 several	 factors.	 The	 first	 of	which	 would	 be	 a	 result	 of	 more	 FUS	 in	 the	 cytoplasm,	 not	 only	 could	 the	availability	 of	 more	 FUS	 create	 the	 opportunity	 for	 new	 aberrant	 protein	interactions	but	also	it	increases	self-self	interaction	and	phase	separation	(Patel	et	al.	2015;	Hofweber	et	al.	2018).	Also,	interactions	which	are	dependent	on	the	C-terminal	 NLS	 could	 be	 reduced	 or	 lost.	 The	 consequences	 of	 this	 altered	interactome	could	result	in	both	of	a	gain	or	a	loss	of	mechanism.	Some	proteins	may	 be	 abnormally	 sequestered	 into	 mutant	 FUS	 granules,	 no	 longer	 able	 to	fulfill	their	normal	function.		Additionally,	altered	RNP	granule	composition	may	result	in	altered	mRNA	processing.		
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1.2.1	Comparison	to	other	interactome	studies		In	 2018,	 Kamelgarn	 and	 colleagues	 expressed	 flag-tagged	 wild	 type	 R495X	 or	P525L	 FUS	 in	 N2a	 cells	 and	 then	 immunoprecipated	 FUS	 (Kamelgarn	 et	 al.	2018).	 They	 found	 an	 increase	 of	 translation	 and	 mRNA	 surveillance-related	proteins	 associated	 with	 mutant	 FUS.	 Our	 data	 shows	 a	 decrease	 in	 FUS	interaction	 in	 mutant	 mice	 in	 a	 few	 ribosomal	 proteins	 (Rplp1	 and	 Rpl23).	Additionally,	 they	 found	 an	 increase	 in	 UPF1	 expression	 and	 phosphorylation,	signaling	 an	 increase	 in	 nonsense	 mediate	 decay	 (NMD).	 Interestingly,	 UPF1	binding	 to	 FUS	 was	 decreased	 in	 FusΔNLS/+	 mice	 cortices.	 The	 discrepancies	between	 the	 two	 studies	 could	 be	 explained	 by	 the	 use	 of	 different	 cell	 types	(neuroblastoma	cell	 line	vs	mouse	cortex)	or	overexpression	of	flag-tagged	FUS	vs.	physiological	expression	levels.		Although	the	fold	changes	of	the	interactions	with	FUS	are	small,	they	are	some	interesting	hits.	 Blokhuis	 et	 al.	 used	biotinylation	 tagging	 to	 examine	FUS	wild	type	 and	 R521C	 interactors	 in	 N2a	 cells.	 Their	 top	 disease-related	 proteins	 of	interest	that	showed	increased	aggregation	with	mutant	FUS	included	several	of	our	 top	 hits	 (Blokhuis	 et	 al.	 2016).	 Fmrp,	 Upf1,	 HuD	 and	 Dhx9	 had	 increased	colocalization	with	FUS	R521C	but	were	all	significantly	decreased	in	binding	to	FUS	 in	 the	 FusΔNLS/-	 cortices.	 	 The	 discrepancy	 between	 the	 increased	 co-aggregation	 seen	 in	 the	 Blokhuis	 data	 and	 the	 decreased	 co-immunoprecipitation	in	our	data	could	be	explain	by	either	the	lack	of	presence	of	 aggregates	 in	 the	 FusΔNLS/+	 cortices	 or	 by	 the	missing	NLS.	Nonetheless,	 the	overlaps	in	changes	of	interactors	between	the	two	mutants	are	interesting.			
1.2.2.	Overlap	with	unmethylated	FUS	interactors		FUS	 is	 normally	 asymmetrically	 dimethylated	 (ADMA-FUS).	 In	 human	ALS-FUS	cases,	normally	methylated	FUS	is	found	in	FUS-positive	inclusions,	while	FTLD-FUS	patients	 have	 an	 accumulation	 of	 unmethylated	 and	monomethylated	 FUS	(Dormann	et	 al.	 2012;	 Scekic-Zahirovic	 et	 al.	 2017;	 Suárez-Calvet	 et	 al.	 2016)	 .	
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Thus,	 FUS	 shows	 an	 altered	 methylation	 status	 in	 FTD-FUS	 patients	 and	 is	hypomethylated.	 Recently,	 our	 group	 has	 shown	 that	 loss	 of	 FUS	 arginine	methylation	promotes	FUS	phase	separation	(Hofweber	et	al.	2018)	and	thus	is	likely	to	promote	FUS	aggregation.				To	 test	whether	 loss	of	FUS	arginine	methylation,	as	seen	 in	FTD-FUS	patients,	causes	other	abnormal	protein-protein	interactions,	Mario	Hofweber	performed	a	 biochemical	 pulldown	 with	 recombinant	 unmethylated	 vs.	 methylated	 MBP-FUS	immobilized	on	MBP-trap	beads	and	nuclear	and	cytosolic	fractions	of	adult	mouse	cortices.	After	stringent	washing,	he	processed	the	protein	samples	on	the	beads	 for	 LC-MS,	 to	 identify	 differential	 interactors	 of	 unmethylated	 vs.	methylated	 (ADMA-modified)	FUS.	 	He	 identified	a	 large	number	of	 interactors	that	bound	more	strongly	to	unmethylated	FUS	and	a	small	number	of	proteins	that	bound	more	strongly	to	methylated	FUS	(unpublished	data).	These	proteins	are	potentially	disease-relevant,	as	their	function	might	be	disturbed	in	FTD-FUS	patients	 by	 the	 aberrant	 interaction	 with	 unmethylated	 FUS.	 Therefore,	 I	compared	 his	 list	 of	 abnormal	 unme-FUS	 interactors	 with	 my	 list	 of	 altered	FusΔNLS/-protein	 interactors,	 as	 this	 comparison	 might	 identify	 proteins	 that	normally	interact	with	FUS,	but	whose	interaction	is	disturbed	in	both	FTD-FUS	and	ALS-FUS.	.	The	overlap	between	my	list	of	altered	interactors	in	the	FUSΔNLS/+	IP	 and	 his	 list	 of	 proteins	 that	 show	 differential	 binding	 to	 unmethylated	 FUS	yielded	4	proteins:	Fam120c,	Hnrnpul2,	Tnpo2	and	Upf1	(Table	4).							
	
	Table	4:	Proteins	that	immunoprecipitate	differentially	in	cortices	of	
FusΔNLS/-	mice	vs	wild	type,	but	also	bind	differentially	to	unmethylated	vs.	
methylated	FUS.	Numbers	are	log2-fold	changes.	
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Interestingly,	all	of	these	proteins	show	increased	binding	to	unmethylated	FUS	relative	to	methylated,	yet,	they	show	a	decreased	binding	to	FUS	in	the	FusΔNLS/-	cortices.	This	could	indicate	that	these	four	proteins	normally	interact	with	FUS,	but	 more	 strongly	 when	 methylation	 is	 lost,	 and	 less	 strongly	 when	 the	 C-terminal	 NLS	 is	 missing.	 Since	 one	 of	 the	 methylated	 RGG	 repeat	 domains	 is	directly	 next	 to	 the	 PY-NLS	 at	 the	 C-terminal	 end	 of	 FUS	 (Figure	 2),	 it	 seems	possible	 that	 these	 proteins	 interact	 with	 FUS	 via	 the	 C-terminal	 RGG3-PY	domain	 and	 that	 these	 interactions	 are	 altered	upon	 loss	 of	RGG3	methylation	and	 NLS	 deletion.	 These	 four	 hits	 could	 be	 followed	 up	 by	 looking	 for	colocalization	using	immunostaining	in	either	a	cell	line	or	primary	neurons.				
1.2.3.	Fus	and	the	proteasome		Ubiquitinated	 inclusions	 are	 a	 hallmark	 pathology	 of	 ALS	 and	 FTD.	 Protein	quality	control	is	maintained	by	two	different	systems,	the	ubiquitin-proteasome	system	 (UPS)	 and	 the	 autophagy-lysosome	 system.	 One	 group	 disrupted	 the	proteasome	 system	 by	 knocking	 out	 a	 component	 of	 the	 26s	 proteasome	 in	motor	neurons.	Disruption	of	the	UPS	in	motor	neurons	resulted	in	an	ALS-like	phenotype	 in	 mice	 (Tashiro	 et	 al.	 2012).	 In	 2015,	 Wang	 and	 colleagues	overexpressed	 either	 FUS	 wild	 type	 or	 P525L	 in	 HEK	 293	 cells,	immunoprecipitated	 FUS	 and	 evaluated	 the	 differential	 interactome	 of	mutant	vs.	 wild	 type	 FUS.	 	 They	 found	 two	 proteasome-related	 proteins	 to	 have	increased	 binding	 to	 FUS	 P525L,	 UBA1	 and	 PSMD12	 (T.	 Wang	 et	 al.	 2015).	Although	both	of	 these	proteins	were	present	 in	our	cytosolic	FUS-IPs,	 there	 is	no	difference	 in	binding	between	wild	 type	and	mutant.	However,	our	RNASeq	showed	an	increase	in	Psme4,	Psmd6,	Psme4	mRNA	in	mutant	FUS	IP	relative	to	wild	type	(Figure	25).	Several	mRNAs	that	encode	for	proteasomal	components	(Figure	27)	have	alternative	splice	isoforms	present	in	the	cytosol	in	the	cortices	of	 FUSΔNLS/+	 mice.	 Finally,	 LC-MS	 showed	 differential	 binding	 of	 several	proteasomal	 components.	 Proteasomal	 subunits	 Psma6,	 Psma7/8,	 Psmb5	 and	Txnl1	 all	 showed	 increased	 interaction	 with	 FUS	 under	 mutant	 conditions	(Figure	33).			
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The	 results	of	 the	RNASeq	and	MS	suggest	 that	FUS	may	 regulate	proteasomal	activity	both	on	the	RNA	and	protein	level.	Is	FUS	regulating	proteasomal	mRNA	localization	and/or	translation?	And	secondly,	is	mutant	FUS	either	sequestering	proteasomal	 subunits,	 inhibiting	 proteasomal	 activity,	 or	 is	 the	 proteasome	trying	 to	 clear	 away	 mutant	 FUS?	 In	 order	 to	 address	 the	 second	 question,	 I	transfected	FUS	KO	HeLa’s	with	either	FUS	wild	type	or	FUS	514x	in	combination	with	 a	 proteasomal	 activity	 reporter.	 	 While	 I	 did	 not	 observe	 a	 difference	between	FUS	wild	type	and	514x,	which	could	have	multiple	reasons,	e.g.that	the	proteasomal	 binding	 differences	were	 cortex-specific	 or	 age-dependent,	 as	 we	observed	them	in	50	day	old	mouse	cortices.	Additionally,	48-72	hours	of	mutant	FUS	expression	may	simply	not	be	enough	time	to	cause	changes	in	the	UPS.		In	 order	 to	 fully	 explore	 the	 possibility	 of	 disruptions	 to	 the	 UPS,	 more	experiments	 would	 be	 need	 to	 be	 conducted.	 The	 Hipp	 lab,	 which	 generously	shared	 the	 construct	with	 us,	 has	 a	 stable	 cell	 line	 expressing	 the	 proteasome	reporter,	 which	 could	 be	 used	 more	 accurately	 measure	 proteasomal	 activity	(using	 flow	 cytometry),	 although	 transfection	 of	 FUS	 constructs	 into	 these	 cell	lines	 would	 results	 in	 overexpression	 of	 FUS	 and	 not	 accurately	 reflect	 the	situation	we	 have	 in	 the	 FusΔNLS/+	vs.	wt	mice.	 A	 preferred	 option	would	 be	 to	transfect	 cultured	 the	 FUSΔNLS/+	 and	 wild	 type	 neurons	 with	 the	 proteasome	activity	 reporter,	 as	 this	 would	 allow	 us	 to	 study	 proteasomal	 activity	 under	conditions	of	stable	FusΔNLS/+	vs.	FUS-wt	expression.	Unfortunately,	I	was	unable	to	derive	primary	neuronal	cultures	 from	the	mice	due	 to	breeding	 issues	 (see	results,	section	4.1)	.		As	 some	proteasomal	mRNAs	differentially	 interact	with	mutant	FUS,	 this	may	alter	 their	 subcellular	 localization	 and	 therefore	 translation.	 Aside	 from	investigating	 proteasomal	 activity,	 one	 could	 also	 look	 at	 the	 localization	 of	proteasomal	components	with	 immunohistochemistry	of	cortical	brain	sections	or	cultured	neurons.			
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1.2.4.	FUS	and	the	Septins		Septins	 are	 cytoskeletal	 GTPases	 that	 can	 form	 into	 heteromeric	 complexes,	filaments	and	rings.	Interacting	with	actin,	microtubules	and	phospholipids,	not	only	 are	 septins	 important	 protein	 scaffolds,	 they	 are	 important	 for	 dendritic	spine	 arborization	 (Mostowy	 and	 Cossart	 2012;	 Kaplan	 et	 al.	 2017).	 Recently,	Ewers	 et	 al.	 demonstrated	 that	 Sept7	 restricts	 membrane	 protein	 flow	 across	dendritic	 spine	necks,	 acting	 as	 a	diffusion	barrier.	 	 In	particular,	 they	 showed	that	presence	of	Sept7	reduces	GluA2	subunit-containing	AMPAR	diffusion	 into	spines	(Ewers	et	al.	2014).	 	Our	data	show	an	 increase	 in	the	binding	of	Fus	to	Sept2,	 3,	 4	 and	 7	 (Figure	 34).	 Additionally,	 through	 correspondence	 with	 the	Ewers	 lab,	 we	 have	 learned	 that	 they	 found	 wild	 type	 FUS	 as	 an	 abundant	protein	 in	 a	 Sept7	 immunoprecipitation	 (unpublished	 results,	 Helge	 Ewers,	Berlin).	 This	 suggests	 that	 FUS	might,	 under	 physiological	 conditions,	 interact	with	Septins	and	play	a	role	in	the	diffusion	barrier	at	dendritic	spine	necks.	This	raises	many	interesting	questions:	What	is	the	role	of	the	Septin-FUS	interaction?	Does	Sept7	also	function	as	a	diffusion	barrier	for	FUS-containing	RNP	granules?	FUS	 has	 been	 found	 in	 complex	 with	 NMDA	 receptor	 complexes	 (Husi	 et	 al.	2000)	and	found	within	spine	heads	(Belly	et	al.	2005),	so	it	will	be	interesting	to	test	 whether	 this	 localization	 is	 affected	 by	 Septins.	 Finally,	 what	 are	 the	functional	consequences	of	 the	stronger	 interaction	of	mutant	FUS	with	Septin,	does	it	affect	the	function	of	Septins	as	a	diffusion	barrier	at	the	spine	neck?	Or	is	mutant	 FUS	 somehow	 getting	 stuck	 on	 the	 diffusion	 barrier	 at	 the	 base	 of	 the	dendritic	 spine	 and	 unable	 to	 properly	 to	 deliver	 its	 target	 mRNAs	 into	 the	spine?		These	questions	would	be	best	addressed	 in	neuronal	 cultures	where	a	 role	of	Sept7	as	a	diffusion	barrier	at	dendritic	spine	necks	has	been	described	(Ewers	et	 al.	 2014).	 Unfortunately,	 since	 we	were	 not	 able	 to	 derive	 enough	 primary	neuronal	cultures	 from	FUSΔNLS/-	mice	due	 to	breeding	problems,	we	attempted	to	 study	 Septins	 in	 HeLa	 cells,	 where	 Septins	 are	 also	 expressed	 and	 regulate	microtubule	stability	(Kremer,	Haystead,	and	Macara	2005)	.	We	did	not	see	any	change	 in	 Sept2	 or	 7	 localization	 after	 48h	 of	 wild-type	 vs.	 mutant	 FUS	
	86	
expression	 and	 no	 co-recruitment	 of	 Septins	 with	 mutant	 FUS	 into	 stress	granules	(Figures	36,	38	and	39).	To	further	explore	the	FUS-Septin	interaction,	one	 could	 perform	 biochemical	 experiments,	 e.g.	 co-IPs	 of	 FUS	 or	 Septins,	 to	validate	 that	 mutant	 FUS	 interacts	 more	 strongly	 than	 FUS-	WT	with	 Septins.	Another	 possibility	 would	 be	 to	 look	 into	 changes	 to	microtubules,	 as	 Septins	were	 shown	 to	 be	 important	 for	microtubule	 stability	 (Kremer,	 Haystead,	 and	Macara	2005).	 Finally,	 it	would	be	 ideal	 to	 study	 the	FUS-Septin	 interaction	 in	primary	neurons	or	brain	slices	from	the	FUSΔNLS/+	mice,	e.g.	by	testing	whether	Sept7	 and	 Sept2	 are	 mislocalized	 or	 whether	 an	 impairment	 of	 diffusion	 into	dendritic	spine	is	seen	in	FUS	mutant	neurons.	.			Glutamate	receptor	regulation	is	also	an	integral	FUS	role.		FUS	regulates	GluA1	mRNA	 stability	 (Udagawa	 et	 al.	 2015),	 FusΔNLS	 binds	 preferentially	 to	 an	alternative	splice	form	of	Gria3	and	finally	FusΔNLS	shows	increased	associated	to	several	members	 of	 the	 septin	 family,	 including	 Sept7.	 Sept7	 forms	 a	 diffusion	barrier	 at	 dendritic	 spine	 necks,	 thereby	 regulating	 GluA2	 spine	 expression	(Ewers	et	al.	2014).		
2.	Conclusion		Not	unexpectedly,	our	results	point	to	defects	of	several	systems	in	young,	early-symptomatic	FusΔNLS/+	mice:	RNA	metabolism,	 transcription,	synaptic	 transport,	signaling	and	proteostasis.	In	conjunction	with	the	preliminary	results	from	our	collaborators	 in	 the	Dupuis	 lab,	 several	mRNA	and	protein	expression	 changes	seem	 to	 point	 to	 involvement	 of	 the	 cholinergic	 system.	 Two	 other	 potentially	affected	 systems	 might	 be	 the	 proteasome	 and	 the	 septin	 cytoskeleton.	Ubiquitinated	 inclusions	 found	 in	 ALS	 and	 FTD,	 as	 well	 as	 the	 disruption	 of	proteasome	activity	leading	to	an	ALS-like	phenotype	(Tashiro	et	al.	2012)	make	proteasomal	 degradation	 a	 promising	 candidate	 pathway.	 As	 the	mice	 used	 in	this	 study	 are	 just	 beginning	 to	manifest	 symptoms,	 it	would	 be	 interesting	 to	follow-up	 with	 additional	 time	 points,	 perhaps	 these	 transcriptomic	 and	proteomic	 changes	 will	 be	 more	 pronounced	 and	 are	 the	 starting	 point	 for	neurodegeneration.	 	
	 87	
IV.	EXPERIMENTAL	PROCEDURES		
1.	Mouse	breeding	and	genotyping		Mice	were	generated	by	the	Dupuis	Lab	(as	described	in	(Scekic-Zahirovic	et	al.	2016)).	The	mouse	colony	was	maintained	by	crossing	male	FusΔNLS/+	mice	with	wild	type	C57BL/6J	female	mice.	Timed	matings	for	cortical	neuron	preparation	were	 performed	 using	 FusΔNLS/+	 mice	 and	 either	 wild	 type	 or	 FusΔNLS/+	 female	offspring	from	the	aforementioned	breeding	scheme.	Genotyping	of	the	mice	was	performed	 using	 ear	 tissue;	 the	 DNA	 was	 extracted	 and	 amplified	 using	 the	Extract	 –N-Amp	 PCR	 Kit	 (Sigma).	 Individual	 mouse	 embryos	 were	 genotyped	using	 the	 cerebellum.	The	primer	 sequences	used	 to	 amplify	 the	 Fus	 locus	 are	listed	 in	 Table	 5	 and	 the	 detailed	 PCR	 protocol	 in	 Table	 6.	 Following	amplification,	 PCR	 products	 underwent	 2%	 agarose	 gel	 electrophoresis.	 The	expected	amplicon	 sizes	are	160	base	pair	 for	wild	 type	and	240	base	pair	 for	mutant.		Primer		 Primer	Sequence	FUSdNLS-Forward	 GAT-TTG-AAG-TGG-GTA-GAT-AGT-GCA-GG		FUSdNLS-Reverse	 CCT-TTC-CAC-ACT-TTA-GTT-TAG-TCA-CAG	
	Temperature	 Time	(mm:ss)	 Cycles	95°C	 03:00	 1	95°C	 01:00	 34	62°C	 01:00	 34	72°C	 01:00	 34	72°C	 10.00	 1		
Table	5:	Primer	Sequences	for	FusΔNLS	genotyping.	
Table	6:	PCR	protocol	for	amplication	of	the	Fus	wild	type	and	FusΔNLS	locus.	
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2.	Subcellular	Fractionation	of	Adult	Mouse	Cortices		Mice	 were	 euthanized	 and	 cortices	 were	 extracted	 and	 fresh	 frozen	 in	 liquid	nitrogen	and	stored	at	-80°C	until	processing.	Cortices	were	removed	from	the	-80°C	and	immediately	chopped	with	a	razor	blade	on	a	glass	petri	dish	over	ice	and	then	placed	into	a	2	mL	dounce	homogenator	containing	ice	cold	hypotonic	buffer	(10	mM	HEPES	pH7.9,	10	mM	KCl,	1.5	mM	MgCl2	and	protease	 inhibitor	mix	(Sigma)).	Cortices	were	gently	and	briefly	dounced	by	moving	the	pestle	up	and	 down	 slowly	 7-10	 times	 (until	 all	 visible	 tissue	was	 solubilized)	 and	 then	allowed	 to	 rest	 for	 10	 minutes	 on	 ice.	 Samples	 were	 then	 transferred	 to	 an	eppendorf	 tube	 and	 vortexed	 several	 times.	 Following	 vortexing,	 the	 samples	were	centrifuged	at	3,000	x	g	for	5	minutes	at	4°C.	The	supernatant	was	removed	to	 another	 tube.	 The	 pellet	 (nuclear	 fraction)	 was	 washed	 one	 time	 with	hypotonic	buffer	and	resuspended	 in	hypertonic	buffer	 (10	mM	HEPES	pH	7.9,	10	 mM	 KCl,	 1.5	 mM	 MgCl2,	 150	 mM	 NaCl,	 0.5%	 NP-40,	 protease	 inhibitor	(Sigma)).	 The	 supernatant	 was	 centrifuged	 at	 14,000	 x	 g	 for	 5	 minutes,	 the	supernatant	from	this	spin	was	then	collected	as	the	cytosolic	fraction.	Samples	were	 either	 stored	 at	 -80°C	 until	 later	 use	 or	 immediately	 used	 for	 FUS	immunoprecipitation	(IP).	In	the	finalized	protocol,	NaCl	to	a	final	concentration	of	150	mM	was	added	to	the	cytosolic	fractions	before	IP		
3.	FUS	Immunoprecipitation	(IP)		The	 first	 trial	 runs	 of	 this	 procedure	 used	 protein	 A	 or	 G	 sepharose	 beads	(Helmholtz	 Antibody	 Core	 Facility),	 blocking	 of	 the	 beads	 with	 1	 ug/ul	 BSA	(Sigma)	 and	 20	 ug/ul	 yeast	 tRNA	 (Invitrogen)	 and	 performing	 the	 IP	 in	 the	presence	of	10%	glycerol.	Control	IgG	(rabbit	or	mouse	IgG,	Santa	Cruz	,	cat.	#sc-2027	and	sc-2025)	tests	used	4	ug	of	either	rabbit	or	mouse	IgG	per	IP.	The	final	immunoprecipitaton	(IP)	procedure	excludes	these	steps	and	was	as	follows:			
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For	 each	 IP	 sample,	 50	 µl	 Protein	 G-linked	 Dynabeads	 (Thermo	 Fisher,	 cat.	 #	1007D)	were	washed	 two	 times	with	phosphate	buffered	 saline	 (PBS).	 4	ug	of	mouse	anti-Fus	Antibody	(Santa	Cruz,	4H11)	was	 incubated	with	 the	beads	 for	1.5	h	on	a	rotating	wheel	at	4°C.	Afterwards,	beads	were	first	washed	two	times	with	 PBS	 and	 then	 with	 0.1	 M	 Borate	 buffer	 pH	 9.	 The	 antibody	 was	 then	covalently	 conjugated	 to	 the	 beads	 by	 adding	 5.2	 mg/ml	 dimethyl	 pimelidate	(DMP,	Sigma)	in	0.1	M	Borate	buffer	pH	9	for	30	minutes	at	room	temperature	with	 occasional	 agitation,	 this	 step	 was	 repeated	 one	 time.	 The	 antibody-conjugated	beads	were	then	washed	two	times	with	50	mM	glycine	pH	2.5	and	stored	in	PBS	at	4°C	until	use.		For	 pre-clearing	 the	 cytosolic	 fraction,	 unbound	 Dynabeads	 were	 washed	 two	times	with	 IP	buffer	 (hypotonic	 buffer	 plus	150	mM	NaCl)	 and	 then	 incubated	with	 the	 cytosolic	 fraction	 for	 1h	 at	 4°C	 on	 a	 rotating	 wheel.	 The	 pre-cleared	cytosolic	 fraction	 was	 removed	 and	 then	 incubated	 with	 of	 the	 antibody-conjugated	 beads	 for	 1.5	 h	 at	 4°C	 while	 rotating.	 Afterwards,	 the	 beads	 were	washed	3	times	with	IP	Buffer.	During	the	final	wash	step,	samples	were	split	in	half	 and	 then	 either	 eluted	with	 room	 temperature	 Tri	 Reagent	 RNA	 Isolation	Reagent	 (Sigma)	 (incubation	 for	 10	 min	 at	 room	 temperature	 and	 then	 the	supernatant	 transferred	 to	 a	 new	 tube)	 or	 by	 boiling	 for	 5	min	 in	 2x	 Laemmli	buffer.	Samples	were	stored	at	-80°C	until	submission	to	the	appropriate	facility.		
4.	RNAseq	library	preparation	and	RNA	Sequencing	analysis		RNA	 in	 Trizol	 (Tri	 Reagent,	 Sigma)	 was	 submitted	 to	 the	 Laboratory	 for	Functional	Genome	Analysis	 (LAFUGA)	at	 the	Gene	Center	Munich.	There,	RNA	was	 isolated	 using	 Direct-zol	 RNA	 Miniprep	 Kit	 (Zymo)	 and	 RNA	 quality	 was	determined	 using	 Nanodrop	 ND-1000	 (ThermoFisher	 Scientific)	 and	2100	Bioanalyzer	 (RNA	 6000	 Nano,	 Agilent).	 cDNA	 library	 preparation	 was	completed	with	 Encore®	 Complete	 RNA-Seq	 Library	Multiplex	 DR	 Systems	 Kit	(NuGEN)	 and	 multiplexed	 sequencing	 was	 performed	 on	 the	 HiSeq	1500	(Illumina)	using	100	bp	single	end	reads.		
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RNA	Sequencing	Analysis	was	performed	by	Dr.	Tobias	Straub	of	the	Biomedical	Center	at	LMU	(on	a	collaborative	basis).		Sequencing	reads	were	aligned	to	the	mm10	 genome	 using	 STAR	 aligner,	 for	 transcript	 level	 analysis,	 the	 transcript	levels	 were	 quantified	 using	 Rsem.	 Following	 normalization	 to	 the	 cytosolic	input,	 differential	 expression	was	 calculated.	 For	 alternative	 splicing,	 following	alignment	 to	 the	 genome,	 Rmats	 was	 used	 to	 calculate	 differential	 splicing	events.	 Gene	 Ontology	 and	 KEGG	 Analysis	 were	 performed	 using	 DAVID	(https://david.ncifcrf.gov/summary.jsp).		
5.	Mass	spectrometry		All	IP	samples	were	submitted	to	the	laboratory	of	Prof.	Stefan	Lichtenthaler	for	sample	preparation	 and	MS	 analysis	 by	Dr.	 Stephan	Müller	 (on	 a	 collaborative	basis).		
5.1	Sample	preparation	for	mass	spectrometry		In	the	first	FUS	IP	experiments,	samples	in	Laemmli	buffer	were	separated	on	a	10%	SDS	PAGE.	The	gels	were	cut	into	six	or	eight	fractions	and	subjected	to	in-gel	 digestion.	 In	 gel	 digestion	 and	 peptide	 purification	 were	 performed	 as	previously	described	 (Shevchenko	et	al.	2006).	Briefly,	proteins	 residing	 in	 the	gel	 were	 denatured	 with	 10	 mM	 dithiothreitol	 (DTT)	 in	 100	 mM	 ammonium	bicarbonate	 (ABC),	 reduced	with	 55	mM	 iodoacetamide	 (IAA)	 in	 100	mM	ABC	and	proteolytic	digestion	was	performed	at	37°C	overnight	using	150	ng	trypsin	per	 fraction.	 40%	acetonitrile	 (ACN)	 supplemented	with	0.1%	 formic	 acid	was	used	to	extract	the	peptides.	Peptides	were	dried	by	vacuum	centrifugation,	and	reconstituted	in	0.1%	formic	acid	for	proteomic	analysis.	Some	in-gel	digestions	could	not	be	analyzed	properly	because	of	contamination	problems.	Therefore,	we	applied	another	sample	preparation	method	(on-bead	digestion)	 for	 the	 final	 experiment	 that	 is	 better	 suited	 to	 remove	contaminations.	Samples	in	Laemmli	buffer	were	subjected	to	a	modified	single-pot	 solid-phase-enhanced	 sample	 preparation	 (SP3)	 protocol	 (Hughes	 et	 al.	2019).	Briefly,	10	µL	of	a	4	µg/µL	bead	slurry	of	Sera-Mag	SpeedBeads	A	and	B	
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(GE	 Healthcare)	 were	 added	 to	 the	 samples.	 Protein	 binding	 to	 the	 magnetic	beads	was	achieved	by	adding	acetonitrile	(ACN)	to	a	final	volume	of	70	%	(v/v)	and	mixing	 at	 1200	 rpm	 at	 24	 °C	 for	 30	 min	 in	 a	 Thermomixer	 (Eppendorf).	Magnetic	 beads	 were	 retained	 in	 a	 DynaMag-2	magnetic	 rack	 (Thermo	 Fisher	Scientific)	and	the	supernatant	was	discarded.	Cystines	were	alkylated	by	adding	25	µL	of	80	mM	iodoactemamide	(Sigma-Aldrich)	and	incubated	at	1200	rpm	at	24	°C	 for	30	min	 in	the	dark	 in	a	Thermomixer.	The	reaction	was	quenched	by	adding	3	µL	of	200	mM	DTT	(Biozol).	Protein	binding	to	the	beads	was	repeated	in	70%	(v/v)	ACN	 for	30	min.	After	 removing	 the	 solvent,	 beads	were	washed	twice	in	200	µL	70%	(v/v)	ethanol	and	twice	in	180	µL	of	100%	(v/v)	ACN.	Next,	250	ng	of	LysC	and	250	ng	of	trypsin	(Promega)	were	added	in	20	µL	of	50	mM	ammonium	bicarbonate	(Sigma).	The	protein	digestion	was	performed	for	16	h	at	 room	 temperature.	 Samples	 were	 acidified	 with	 formic	 acid	 to	 a	 final	concentration	 of	 1%	 (v/v)	 and	 placed	 in	 the	magnetic	 rack.	 The	 supernatants	were	transferred	into	fresh	0.5	mL	protein	lobind	tubes	(Eppendorf).	A	volume	of	 20	 µL	 of	 2%	 (v/v)	 dimethyl	 sulfoxide	was	 added	 to	 the	 beads	 and	 samples	were	subjected	to	sonication	for	30	s	in	a	water	bath.	Tubes	were	placed	in	the	magnetic	 rack	 and	 the	 supernatants	 were	 transferred	 to	 the	 same	 tubes.	 The	samples	were	dried	in	a	vacuum	centrifuge	and	dissolved	in	20	µL	0.1%	formic	acid.		
5.2	LC-MS/MS	analysis		Samples	 were	 analyzed	 by	 LC-MS/MS	 for	 relative	 label	 free	 protein	quantification.	A	volume	of	10	µL	per	sample	was	separated	on	a	nanoLC	system	(EASY-nLC	1200,	Thermo	Scientific)	using	an	 in-house	packed	C18	column	(30	cm	 x	 75	 µm	 ID,	 ReproSil-Pur	 120	 C18-AQ,	 1.9	 µm,	 Dr.	 Maisch	 GmbH)	 with	 a	binary	gradient	of	water	(A)	and	acetonitrile	(B)	containing	0.1%	formic	acid	at	50°C	 column	 temperature	 and	 a	 flow	 rate	 of	 250	 nl/min	 (gradient	 for	 final	experiment:	0	min.,	2.4%	B;	2	min.,	4.8%	B;	92	min.,	24%	B;	112	min.,	35.2%	B;	121	min.,	60%	B;	gradient	for	in-gel	digested	samples:	0	min,	2%	B;	3:30	min	5%	B;	48:30	min,	25%	B;	59:30,	35%	B;	64:30,	60%	B).		
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The	nanoLC	was	coupled	online	via	a	nanospray	flex	ion	source	(Proxeon	–	part	of	Thermo	Scientific)	equipped	with	a	PRSO-V2	column	oven	(Sonation)	to	a	Q-Exactive	 (in-gel	 digestion	 1),	 a	 Velos	 Pro	Orbitrap	 (in-gel	 digestion	 2),	 or	 a	 Q-Exactive	HF	(SP3	digestion)	mass	spectrometer	(Thermo	Scientific).		On	 the	Velo	Pro	Orbitrap	mass	 spectrometer,	 full	MS	 spectra	were	acquired	 in	profile	mode	at	a	resolution	of	60,000	covering	a	m/z	range	of	300-1400.	The	ten	most	 intense	 peptide	 ions	 per	 full	 MS	 scan	 were	 chosen	 for	 collision	 induced	dissociation	 (CID)	 within	 in	 the	 ion	 trap	 (isolation	 width:	 2	 m/z;	 normalized	collision	 energy:	 35%;	 activation	 q:	 0.25;	 activation	 time:	 10	 ms).	 A	 dynamic	exclusion	of	60	s	was	applied	for	peptide	fragmentation.	On	the	Q-Exactive	mass	spectrometer,	full	MS	spectra	were	acquired	at	a	resolution	of	70,000.	The	top	10	peptide	 ions	 were	 chosen	 for	 Higher-energy	 C-trap	 Dissociation	 (HCD)	with	 a	normalized	collision	energy	of	25%	and	an	 isolation	width	of	2	m/z.	Fragment	ion	spectra	were	acquired	at	a	resolution	of	17,500.	A	dynamic	exclusion	of	60	s	was	used	for	peptide	fragmentation.	On	the	Q-Exactive	HF,	full	MS	spectra	were	acquired	 at	 a	 resolution	 of	 120,000.	 The	 top	 15	 peptide	 ions	were	 chosen	 for	Higher-energy	C-trap	Dissociation	 (HCD)	with	 a	 normalized	 collision	 energy	of	26%	and	an	isolation	width	of	1.6	m/z.	Fragment	ion	spectra	were	acquired	at	a	resolution	 of	 15,000.	 A	 dynamic	 exclusion	 of	 120	 s	 was	 used	 for	 peptide	fragmentation.		
5.3	LC-MS/MS	data	analysis	and	label	free	quantification			The	 raw	 data	 was	 analyzed	 by	 the	 software	 Maxquant	 (maxquant.org,	 Max-Planck	Institute	Munich)	version	and	1.5.5.1	(Cox	et	al.	2014).	The	MS	data	was	searched	 against	 a	 reviewed	 canonical	 fasta	 database	 of	 Mus	 musculus	 from	UniProt	 (downloads:	 In-gel	 Digestion	 1:	 June	 08th	 2016,	 16798	 entries	 In-gel	Digestion	2:	January	11th	2017,	16843	entries;	SP3	digestion:	January	17th	2018,	16954	 entries).	 Trypsin	 was	 defined	 as	 protease.	 Two	missed	 cleavages	 were	allowed	for	the	database	search.	The	option	first	search	was	used	to	recalibrate	the	 peptide	masses	within	 a	window	 of	 20	 ppm.	 For	 the	main	 search	 peptide	mass	tolerances	were	set	to	4.5	ppm.	The	fragment	mass	tolerances	were	set	to	
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20	 ppm	 for	 samples	 analyzed	 on	 Q-Exactive	 instruments	 and	 to	 0.5	 Da	 for	samples	 analyzed	 on	 the	 Velos	 Pro	 Orbitrap	 mass	 spectrometer.	Carbamidomethylation	 of	 cysteine	 was	 defined	 as	 static	 modification.	Acetylation	of	the	protein	N-term	as	well	as	oxidation	of	methionine	were	set	as	variable	modifications.	The	 false	discovery	 rate	 for	both	peptides	 and	proteins	was	 adjusted	 to	 less	 than	 1%.	 Label	 free	 quantification	 (LFQ)	 of	 proteins	required	at	least	two	ratio	counts	of	razor	peptides.	Only	unique	peptides?	were	used	 for	 quantification.	 The	 option	 “match	 between	 runs”	was	 enabled	with	 a	matching	 time	of	1	min.	Samples	were	normalized	separately	 for	each	batch	of	biological	replicates.		In	a	test	experiment,	three	different	antibodies	for	Fus	(mouse	4H11	and	rabbit	A300-294	and	11570-1-AP)	and	two	control	IgGs	(mouse	and	rabbit	IgG)		were	used	 for	 the	 Fus	 Co-IP.	 The	 LFQ	 ratios	 of	 the	 different	 antibodies	 against	 the	mouse	or	rabbit	IgG	controls	were	calculated	for	each	protein.	The	three	protein	LFQ	ratios	were	 log2	 transformed	and	a	one-sample	T-test	 against	 a	µ0	of	 zero	was	applied	separately	 for	mouse	and	rabbit	normalized	ratios	 to	estimate	 the	significance	of	the	protein	abundance	differences.		In	a	second	test	experiment,	mouse	4H11	antibody	against	Fus	and	two	mouse	IgG	controls	were	used	in	the	Co-IP	experiment.	Therefore,	protein	LFQ	ratios	of	the	two	Co-IPs	against	the	related	control	IgG	identify	were	calculated	to	identify	potential	binding	partners	of	FUS.		In	the	final	experiment,		the	FUS	mouse	4H11	antibody	was	used	on	wild-type	vs.	FusΔNLS/-samples,	protein	LFQ	intensities	were	log2	transformed,	the	mean	log2	LFQ	ratio	was	calculated	and	a	Student’s	T-test	was	applied	to	identify	significant	changes	between	samples	of	FusΔNLS/-and	wild	type	mice.		
6.	SDS-PAGE	and	Immunoblotting		Laemmli	 buffer	was	 added	 to	 the	 samples,	which	were	 then	 run	 on	 SDS-PAGE	gels,	 either	 self-made	 or	 pre-cast	 AnyKD	 gels	 (Bio-Rad).	 Protein	 was	 then	
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transferred	to	a	nitrocellulose	membrane	(Bio-Rad)	by	either	wet	transfer	(using	a	 Mini	 Trans-Blot®	 Electrophoretic	 Transfer	 System	 (Bio-Rad)	 or	 semi-dry	transfer	 (using	 the	 Bio-Rad	 Trans	 Blot	 Turbo).	 The	membrane	was	 blocked	 in	Tris	 buffered	 saline	with	Tween-20	 (TBS-T)	with	 5%	milk	 and	 then	 incubated	with	 the	 specified	primary	antibody	overnight	at	4°C	or	 for	1h	at	RT	and	after	washing	 (3	 times	 in	 TBS-T)	with	 a	 suitable	 secondary	 antibody	 (see	 Table	 6).	Blots	were	 imaged	using	 the	Licor’s	Odyssy	CLx	 imaging	 system.	Densitometry	measurements	were	carried	out	in	ImageJ.		
7.	Optiprep	Gradient	and	High	Speed	Centrifugation		A	 15-30%	 Optiprep	 gradient	 (hypotonic	 buffer,	 Optiprep	 (Sigma),	 H2O,	 1	 mM	DTT,	protease	 inhibitor	 (Roche))	was	prepared	 in	polyallomer	 tubes.	Briefly,	 a	15%	 and	 30%	 Optiprep	 solution	 (in	 hypotonic	 buffer	 with	 1	 mM	 DTT	 and	protease	inhibitor	were	prepared,	the	15%	solution	was	gently	layered	onto	the	30%	solution.	Samples,	treated	with	or	without	RNAse	I	(Thermo	Fisher)	for	1h	at	 37°C,	 were	 gently	 placed	 on	 top	 of	 the	 gradient	 and	 ultracentrifuged	 at	197,500	x	g	for	2.5	h	at	4°C	and	then	1	mL	fractions	were	collected	from	top	to	bottom.		To	extract	proteins	from	each	fraction,	a	chloroform-methanol	precipitation	was	performed.	 The	 samples	 were	 centrifuged	 and	 the	 pellet	 was	 resuspended	 in	Laemmli	and	then	analyzed	by	SDS-PAGE	and	immunoblotting.		For	 high	 speed	 centrifugation,	 nuclear	 and	 cytosolic	 fractions	 were	 either	untreated,	 treated	 with	 RNAse	 I	 (Thermo	 Fisher)	 or	 DNAse	 I	 (NEB)	 for	 1h	 at	37°C.	Samples	were	then	centrifuged	at	20,000	x	g	for	15	min	at	4°C,	a	fraction	of	the	 supernatant	 and	 the	 pellet	were	 collected	 for	 SDS-PAGE	 and	Western	 blot	analysis.	 The	 remaining	 supernatant	 was	 transferred	 to	 a	 new	 tube	 and	centrifuged	 at	 100,000	 x	 g	 for	 30	min	 at	 4°C.	 Supernatant	 and	 pellet	 fractions	were	then	analyzed	by	SDS-PAGE	and	Western	blot	analysis.		
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8.	Cell	Culture		HeLa	cells	and	FUS	knockout	HeLa	cells	 (created	as	described	 in	Suarez-Calvet	2017)	 were	 cultured	 in	 Dulbecco’s	 Modified	 Eagle	 Medium	 (DMEM)	 with	Glutamax	(Life	Technologies)	supplemented	with	10%	fetal	calf	serum	(FCS,	Life	Technologies)	 and	 Gentamycin	 (10	 mg/ml,	 Invitrogen).	 SH-SY5Y	 cells	 were	cultured	 in	 DMEM/F12	 with	 Glutamax	 plus	 10%	 FCS	 (Life	 Technologies)	 and	Gentamycin	(10	mg/ml,	Invitrogen).		All	 transfections	 were	 performed	 in	 24	 well	 plates	 with	 Turbofect	 (Thermo	Fisher)	with	a	maximum	of	500	ng/well	of	DNA.	Double	transfections	with	FUS	and	Septin	constructs	were	performed	at	2:1	ratio	and	double	transfection	with	FUS	constructs	and	the	proteasome	activity	reporter,	Ub-G76V-GFP,	were	carried	out	at	a	3:1	ratio.	Transfected	cells	were	analyzed	48h	days	post-transfection.			
9.	Primary	Neuronal	Culture		Timed	 pregnancies	 of	 either	 C57BL/6J	 wild	 type	 x	 wild	 type	 or	 C57BL/6J	FusΔNLS/-	x	wild	type	were	initiated.	At	e15.5,	pregnant	females	were	sacrificed	by	CO2	followed	by	cervical	dislocation.	Embryos	were	extracted	and	cortices	were	removed	 into	 Hank’s	 Balanced	 Salt	 Solution	 (HBSS,	 Thermo	 Fisher).	 The	cerebellum	was	 removed	 for	 genotyping	 (as	 described	 in	 section	 XX).	 Cortices	were	then	incubated	with	trypsin	(Thermo	Fisher)	for	10	min	at	37°C	and	then	resuspended	in	Neurobasal	medium	plus	10%	horse	serum	(Thermo	Fisher)	and	triturated	with	a	fire-blasted	pipette	(Figure	42).	Cells	were	filtered	with	a	100	um	 and	 then	 a	 70	 um	 filter,	 counted	 and	 plated	 onto	 poly-D-lysine	 coated	coverslips.	Poly-D-lysine	coverslips	were	prepared	by	adding	1	mg/mL	poly-D-lysine	 in	 borate	 buffer	 for	 1	 hour.	 Coverslip	 were	 then	 rinsed	 one	 time	 with	Millipore	water	and	then	treated	with	UV	light	to	sterilize.		
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10.	Immunostaining		All	steps	were	performed	at	room	temperature.	Cell	lines	were	washed	one	time	in	PBS	then	fixed	in	4%	formaldehyde,	neurons	in	4%	formaldehyde/4%	sucrose	in	PBS	for	10	minutes.	Permeabilization	of	the	cell	 lines	and	neurons	was	done	with	0.2%	Triton	X-100	or	0.1%	Triton	X-100	in	PBS,	respectively.	All	wash	steps	were	performed	in	PBS	with	0.1%	saponin	(PBSS).	Cells	were	blocked	with	PBSS	plus	5%	donkey	serum.	Primary	and	secondary	antibodies	were	diluted	in	PBSS	plus	10%	blocking	solution	and	applied	for	1h	or	30	min,	respectively.	Coverslips	were	mounted	onto	glass	slides	using	ProLong	Diamond	Antifade	Reagent	with	DAPI	(Invitrogen)	and	dried	at	room	temperature	overnight.		
11.	Fluorescence	Microscopy		Confocal	 microscopy	 was	 performed	 at	 the	 Bioimaging	 core	 facility	 of	 the	Biomedical	Center	with	an	inverted	Leica	SP8,	equipped	with	lasers	for	405,	488,	552	and	638	nm	excitation.	 Images	were	acquired	using	a	63x1.4	oil	objection.		
Figure	42:		Cortical	neuron	dissociation	workflow.	A	timed	mating	between	adult	mice	was	set	up,	embryos	were	taken	at	E15.5	and	cortices	dissected	into	Hanks	Balanced	Salt	Solution	(HBSS).	Cortices	were	trypsinized	at	37°C	for	10	minutes.	and	neurobasal	medium	+	10%	horse	serum	were	added	for	quenching.	The	cortices	were	triturated,	the	neurons	passed	through	a	70	µm	filter,	centrifuged	for	3	minutes	at	500	x	g	and	then	resuspended	in	neurobasal	medium	+	B27	supplement+	glutamax.	The	neurons	were	cultured	up	to	10	days	with	one	50%	medium	change.		
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Acquired	z-stacks	were	deconvolved	using	Hyugens	Essential	Software.	Single	z-planes	were	then	adjusted	for	brightness	in	Fiji.		
12.	Antibodies		 Name	 Company	Fus	(4H11)	 Santa	Cruz	Fus	(A300-302)	 Bethyl	Fus	(A300-294)	 Bethyl	Fus	(19B2)	 Ruepp	Lab	Fus	 Ruepp	Lab	Fus	(11570-1-AP)	 Proteintech	Fus	 Abcam	HuD	(24992-1-AP)	 Proteintech	Caprin2	(20766-1-AP)	 Proteintech	Tia1	 Santa	Cruz	Sept2	(11397-1-AP)	 Proteintech	Sept7	(18991)	 IBL	HnRNPul1	(10578-1-AP)	 Proteintech	Histone	H3	 Abcam	GAPDH	(10F4)	 Helmholtz	 Center	 Munich	 Antibody	Core	Facility	Alexa	488	Donkey	anti-rabbit	 Invitrogen	Alexa	488	Donkey	anti-mouse	 Invitrogen	Alexa	555	Donkey	anti-rabbit	 Invitrogen	Alexa	555	Donkey	anti-mouse	 Invitrogen	Alexa	647	Donkey	anti-mouse	 Invitrogen	Alexa	647	Donkey	anti-rabbit	 Invitrogen	Alexa	647	Donkey	anti-goat	 Invitrogen	IRDye	680RD	Donkey	anti-mouse	IgG	 LI-COR	IRDye	800VW	Donkey	anti-mouse	IgG	 LI-COR	IRDye	800VW	Donkey	anti-rabbit	IgG	 LI-COR			 	Table	6:	Antibodies	used	in	this	thesis.	
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